

# Functional exhaustion of antiviral lymphocytes in COVID

Cellular and Molecular Immunology

17, 533-535

DOI: [10.1038/s41423-020-0402-2](https://doi.org/10.1038/s41423-020-0402-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. Shock, 2020, 54, 438-450.	1.0	19
2	Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. Frontiers in Immunology, 2020, 11, 577442.	2.2	27
3	Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review. Critical Care, 2020, 24, 594.	2.5	34
4	Angiotensinâ€converting enzyme 2: A protective factor in regulating disease virulence of SARSâ€COVâ€2. IUBMB Life, 2020, 72, 2533-2545.	1.5	15
5	Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity. Frontiers in Microbiology, 2020, 11, 603509.	1.5	34
6	Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. International Immunopharmacology, 2020, 89, 107082.	1.7	23
7	The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Medical Hypotheses, 2020, 145, 110345.	0.8	81
8	Clinical characteristics and survival analysis in critical and non-critical patients with COVID-19 in Wuhan, China: a single-center retrospective case control study. Scientific Reports, 2020, 10, 17524.	1.6	21
9	Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. Clinical Microbiology Reviews, 2020, 34, .	5.7	28
10	Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Advances, 2020, 4, 5035-5039.	2.5	92
11	&lt;p&gt;Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine&lt;/p&gt;. ImmunoTargets and Therapy, 2020, Volume 9, 143-149.	2.7	7
12	Harnessing Memory NK Cell to Protect Against COVID-19. Frontiers in Pharmacology, 2020, 11, 1309.	1.6	31
13	On the genetics and immunopathogenesis of COVID-19. Clinical Immunology, 2020, 220, 108591.	1.4	32
14	Repurposing anticancer drugs for the management of COVID-19. European Journal of Cancer, 2020, 141, 40-61.	1.3	59
15	Azithromycin: The First Broad-spectrum Therapeutic. European Journal of Medicinal Chemistry, 2020, 207, 112739.	2.6	64
16	Characteristics of immune cells and cytokines in patients with coronavirus disease 2019 in Guangzhou, China. Human Immunology, 2020, 81, 702-708.	1.2	28
17	SARS-CoV-2 and coagulation disorders in different organs. Life Sciences, 2020, 260, 118431.	2.0	94
18	Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action. Life Sciences, 2020, 262, 118493.	2.0	41

#	ARTICLE	IF	CITATIONS
19	Techniques and Strategies for Potential Protein Target Discovery and Active Pharmaceutical Molecule Screening in a Pandemic. <i>Journal of Proteome Research</i> , 2020, 19, 4242-4258.	1.8	9
20	COVID-19 Infection: Concise Review Based on the Immunological Perspective. <i>Immunological Investigations</i> , 2020, , 1-20.	1.0	11
21	Severe COVID-19: what have we learned with the immunopathogenesis?. <i>Advances in Rheumatology</i> , 2020, 60, 50.	0.8	53
22	COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188412.	3.3	4
23	What's Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses. <i>Frontiers in Immunology</i> , 2020, 11, 2147.	2.2	131
24	Selenium and selenoproteins in viral infection with potential relevance to COVID-19. <i>Redox Biology</i> , 2020, 37, 101715.	3.9	126
25	Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in". <i>Frontiers in Immunology</i> , 2020, 11, 2132.	2.2	96
26	&lt;p&gt;Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3243-3254.	1.1	20
27	Immune system changes during COVID-19 recovery play key role in determining disease severity. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842096649.	1.0	27
28	COVID-19 and Oral Fluids. <i>Frontiers in Dental Medicine</i> , 2020, 1, .	0.5	0
29	The pandemic exposes human nature: 10 evolutionary insights. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27767-27776.	3.3	57
30	Two distinct immunopathological profiles in autopsy lungs of COVID-19. <i>Nature Communications</i> , 2020, 11, 5086.	5.8	230
31	Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. <i>European Journal of Neurology</i> , 2020, 28, 3503-3516.	1.7	20
32	Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0239802.	1.1	74
33	The Good, The Bad and The Ugly: A Mathematical Model Investigates the Differing Outcomes Among CoVID-19 Patients. <i>Journal of the Indian Institute of Science</i> , 2020, 100, 673-681.	0.9	11
34	Herpes zoster ophthalmicus in COVID-19 patients. <i>International Journal of Dermatology</i> , 2020, 59, 1545-1546.	0.5	32
35	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. <i>Lancet, The</i> , 2020, 396, 1595-1606.	6.3	511
36	Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?-A Case-Control Study. <i>Journal of the American College of Nutrition</i> , 2021, 40, 724-731.	1.1	94

#	ARTICLE	IF	CITATIONS
37	COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 211.	1.5	170
38	CYTOMEGALOVIRUS-INDUCED GASTROINTESTINAL BLEEDING AND PANCREATITIS COMPLICATING SEVERE COVID-19 PNEUMONIA: A PARADIGMATIC CASE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020060.	0.5	19
40	Exploring the causes of mild COVID-19 involvement in pediatric patients. <i>New Microbes and New Infections</i> , 2020, 37, 100741.	0.8	8
41	Making a case for using $\hat{I}^3\hat{T}$ T cells against SARS-CoV-2. <i>Critical Reviews in Microbiology</i> , 2020, 46, 689-702.	2.7	20
42	The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. <i>Journal of Neuroimmunology</i> , 2020, 346, 577323.	1.1	21
43	Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine. <i>ACS Central Science</i> , 2020, 6, 1341-1347.	5.3	11
44	A comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23483.	0.9	20
45	Haematological manifestations of COVID-19: From cytopenia to coagulopathy. <i>European Journal of Haematology</i> , 2020, 105, 540-546.	1.1	77
46	Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis. <i>Frontiers in Immunology</i> , 2020, 11, 1472.	2.2	38
47	Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. <i>Rheumatology International</i> , 2020, 40, 1539-1554.	1.5	90
48	Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals. <i>Headache</i> , 2020, 60, 1697-1704.	1.8	57
49	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <i>Science</i> , 2020, 369, .	6.0	1,280
50	Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2793-2795.	2.0	74
51	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. <i>Life Sciences</i> , 2020, 257, 118058.	2.0	11
52	Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , 2020, 57, 102885.	2.7	109
53	Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5026.	1.2	55
54	Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1 $\alpha$ /Glycolysis-Dependent Axis. <i>Cell Metabolism</i> , 2020, 32, 437-446.e5.	7.2	578
55	High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. <i>Frontiers in Immunology</i> , 2020, 11, 1660.	2.2	48

#	ARTICLE	IF	CITATIONS
56	Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort study. <i>British Journal of Haematology</i> , 2020, 190, e201-e204.	1.2	12
57	Elevated interleukin-6, interleukin-10 and neutrophil-lymphocyte ratio as identifiers of severe coronavirus disease 2019. <i>Immunology</i> , 2020, 160, 221-222.	2.0	5
58	Tea Bioactive Modulate Innate Immunity: In Perception to COVID-19 Pandemic. <i>Frontiers in Immunology</i> , 2020, 11, 590716.	2.2	50
59	Vitamin D3 as Potential Treatment Adjuncts for COVID-19. <i>Nutrients</i> , 2020, 12, 3512.	1.7	39
60	Potential approaches to combat COVID-19: a mini-review. <i>Molecular Biology Reports</i> , 2020, 47, 9939-9949.	1.0	12
61	The immunology of SARS-CoV-2 infections and vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101422.	2.7	85
62	The bioenergetics of COVID-19 immunopathology and the therapeutic potential of biophysical radiances. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2020, 213, 112083.	1.7	6
63	Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E. <i>Human Immunology</i> , 2020, 81, 697-701.	1.2	20
64	Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+T cells. <i>Scientific Reports</i> , 2020, 10, 20363.	1.6	21
65	Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. <i>Frontiers in Immunology</i> , 2020, 11, 610300.	2.2	149
66	Cardiac surgery outcomes in patients with coronavirus disease 2019 (COVID-19): A case-series report. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 1085-1092.e3.	0.4	28
67	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. <i>Frontiers in Microbiology</i> , 2020, 11, 588409.	1.5	19
68	Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. <i>Experimental Gerontology</i> , 2020, 142, 111147.	1.2	73
69	Antibody-Based Immunotherapeutic Strategies for COVID-19. <i>Pathogens</i> , 2020, 9, 917.	1.2	12
70	Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19. <i>Clinical and Translational Immunology</i> , 2020, 9, e1204.	1.7	59
71	Immunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. <i>Frontiers in Immunology</i> , 2020, 11, 579220.	2.2	115
72	Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response. <i>Frontiers in Immunology</i> , 2020, 11, 1748.	2.2	169
73	Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. <i>Pediatric Pulmonology</i> , 2020, 55, 2556-2564.	1.0	40

#	ARTICLE	IF	CITATIONS
74	COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduction and Targeted Therapy, 2020, 5, 128.	7.1	535
75	Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Frontiers in Immunology, 2020, 11, 1708.	2.2	835
76	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in Immunology, 2020, 11, 1817.	2.2	189
77	Molecular Regulation of NK Cell Maturation. Frontiers in Immunology, 2020, 11, 1945.	2.2	35
78	Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. British Journal of Pharmacology, 2020, 177, 4899-4920.	2.7	73
79	The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions. Frontiers in Immunology, 2020, 11, 1692.	2.2	19
80	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 5224.	1.8	42
81	Minireview Exploring the Biological Cycle of Vitamin B3 and Its Influence on Oxidative Stress: Further Molecular and Clinical Aspects. Molecules, 2020, 25, 3323.	1.7	19
82	Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatology, The, 2020, 2, e518-e519.	2.2	44
83	T cell responses in patients with COVID-19. Nature Reviews Immunology, 2020, 20, 529-536.	10.6	706
84	The Metabolic Changes and Immune Profiles in Patients With COVID-19. Frontiers in Immunology, 2020, 11, 2075.	2.2	37
85	Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV. Reviews in Medical Virology, 2020, 30, 1-9.	3.9	52
86	Development and validation of prognosis model of mortality risk in patients with COVID-19. Epidemiology and Infection, 2020, 148, e168.	1.0	45
87	CAR-NK Therapy: Translating a Novel Immunotherapy Treatment to Solid Organ Transplantation. Transplantation, 2020, 104, 1523-1524.	0.5	2
88	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. Frontiers in Immunology, 2020, 11, 1991.	2.2	124
89	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. Life Sciences, 2020, 258, 118166.	2.0	79
90	Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73- Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes. Cells, 2020, 9, 1750.	1.8	48
91	Acute monoclonal gammopathy in severe COVID-19. Hematology, Transfusion and Cell Therapy, 2020, 42, 218-220.	0.1	10

#	ARTICLE	IF	CITATIONS
92	Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. <i>Science</i> , 2020, 369, 1210-1220.	6.0	947
93	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. <i>Vaccines</i> , 2020, 8, 443.	2.1	16
94	Natural killer cell responses to emerging viruses of zoonotic origin. <i>Current Opinion in Virology</i> , 2020, 44, 97-111.	2.6	11
95	Host-directed therapies: a potential solution to combat COVID-19. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1117-1120.	1.4	8
96	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. <i>Cancers</i> , 2020, 12, 2237.	1.7	71
97	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. <i>Cell</i> , 2020, 183, 158-168.e14.	13.5	1,561
98	Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 3149-3161.	2.6	54
99	Immune Response and COVID-19: A mirror image of Sepsis. <i>International Journal of Biological Sciences</i> , 2020, 16, 2479-2489.	2.6	60
100	The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?. <i>Medical Hypotheses</i> , 2020, 143, 110129.	0.8	10
101	Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster) Tj ETQq1_1_0.784314 rgBT 0.1479	1.4	79
102	The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19. <i>Clinical and Translational Medicine</i> , 2020, 10, e200.	1.7	115
103	Why Severe COVID-19 Patients Are at Greater Risk of Developing Depression: A Molecular Perspective. <i>Neuroscientist</i> , 2020, , 107385842096789.	2.6	31
104	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 575404.	1.8	4
105	Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness. <i>Frontiers in Immunology</i> , 2020, 11, 580987.	2.2	46
106	Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110914.	2.5	24
107	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	1,193
108	What is the novel coronavirus disease 2019 (COVID-19) that paralyze the world?. <i>Reviews in Medical Microbiology</i> , 2020, 31, 234-241.	0.4	2
109	Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. <i>Cell</i> , 2020, 183, 1479-1495.e20.	13.5	449

#	ARTICLE	IF	CITATIONS
110	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <i>International Immunopharmacology</i> , 2020, 88, 106980.	1.7	31
111	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. <i>Cell Death and Disease</i> , 2020, 11, 921.	2.7	96
112	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 562264.	2.2	8
113	Immune Correlates of COVID-19 Control. <i>Frontiers in Immunology</i> , 2020, 11, 569611.	2.2	21
114	An Effective COVID-19 Vaccine Needs to Engage T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 581807.	2.2	75
115	Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD). <i>Frontiers in Immunology</i> , 2020, 11, 587517.	2.2	49
116	A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019. <i>Frontiers in Immunology</i> , 2020, 11, 572635.	2.2	11
117	Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients. <i>Scientific Reports</i> , 2020, 10, 18277.	1.6	25
118	Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. <i>Open Biology</i> , 2020, 10, 200160.	1.5	232
119	SARS-CoV-2 Pandemic Impacts on NASA Ground Operations to Protect ISS Astronauts. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3247-3250.	2.0	8
120	SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. <i>Cells</i> , 2020, 9, 1975.	1.8	69
121	Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2980-2991.	1.4	24
122	Natural Killer Cell Dysfunction and Its Role in COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6351.	1.8	129
123	Immune-Mediated Coagulopathy in COVID-19 Infection. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 838-840.	1.5	12
124	Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. <i>Journal of Immunology</i> , 2020, 205, 2566-2575.	0.4	16
125	The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. <i>Journal of Translational Medicine</i> , 2020, 18, 359.	1.8	20
126	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and “New Old Friends”. <i>Frontiers in Immunology</i> , 2020, 11, 2059.	2.2	18
127	Complex Immunometabolic Profiling Reveals the Activation of Cellular Immunity and Biliary Lesions in Patients with Severe COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3000.	1.0	2



#	ARTICLE	IF	CITATIONS
128	The role of Interleukin 6 inhibitors in therapy of severe COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110698.	2.5	77
129	Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19. <i>Medical Hypotheses</i> , 2020, 144, 110161.	0.8	22
130	Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. <i>Microbes and Infection</i> , 2020, 22, 515-524.	1.0	23
131	Immunological features of coronavirus disease 2019 in patients with cancer. <i>European Journal of Cancer</i> , 2020, 139, 70-80.	1.3	13
132	Characterization of KIR <sup>+</sup> NKG2A <sup>+</sup> Eomes <sup>+</sup> NK-like CD8 <sup>+</sup> T cells and their decline with age in healthy individuals. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 467-475.	0.7	8
133	Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. <i>PLoS Pathogens</i> , 2020, 16, e1008820.	2.1	21
134	Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). <i>Future Microbiology</i> , 2020, 15, 1287-1305.	1.0	86
135	Improving Non-specific Immunity to Coronavirus Disease (COVID-19) by the Novelty, Diversity, and Quantity of Antigen. <i>Frontiers in Public Health</i> , 2020, 8, 393.	1.3	1
136	Immune responses during COVID-19 infection. <i>Oncolmmunology</i> , 2020, 9, 1807836.	2.1	103
137	The Immune Response and Immunopathology of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 2037.	2.2	137
138	Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?. <i>Biology</i> , 2020, 9, 243.	1.3	6
139	Abnormal immunity of non-survivors with COVID-19: predictors for mortality. <i>Infectious Diseases of Poverty</i> , 2020, 9, 108.	1.5	94
140	Low Baseline Pulmonary Levels of Cytotoxic Lymphocytes as a Predisposing Risk Factor for Severe COVID-19. <i>MSystems</i> , 2020, 5, .	1.7	9
141	A Model for SARS-CoV-2 Infection with Treatment. <i>Computational and Mathematical Methods in Medicine</i> , 2020, 2020, 1-11.	0.7	34
142	Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 1109-1119.	2.0	62
143	The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. <i>Frontiers in Immunology</i> , 2020, 11, 2033.	2.2	69
144	COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy. <i>Immunotherapy</i> , 2020, 12, 1133-1138.	1.0	10
145	No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. <i>Nanomedicine</i> , 2020, 15, 2411-2427.	1.7	19

#	ARTICLE	IF	CITATIONS
146	Covid-19: Perspectives on Innate Immune Evasion. <i>Frontiers in Immunology</i> , 2020, 11, 580641.	2.2	113
147	Drug similarity and structure-based screening of medicinal compounds to target macrodomain-I from SARS-CoV-2 to rescue the host immune system: a molecular dynamics study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-15.	2.0	12
148	C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis. <i>Translational Medicine Communications</i> , 2020, 5, 14.	0.5	6
149	Immunopathogenesis of COVID-19: Summary and Possible Interventions. <i>Frontiers in Immunology</i> , 2020, 11, 564925.	2.2	22
150	A dynamic COVID-19 immune signature includes associations with poor prognosis. <i>Nature Medicine</i> , 2020, 26, 1623-1635.	15.2	765
151	Immunotherapy for SARS-CoV-2: potential opportunities. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1111-1116.	1.4	35
152	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. , 2020, 2, e0178.		34
153	The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research. <i>SLAS Technology</i> , 2020, 25, 522-544.	1.0	18
154	Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020047.	0.5	12
155	Longitudinal Characteristics of T Cell Responses in Asymptomatic SARS-CoV-2 Infection. <i>Virologica Sinica</i> , 2020, 35, 838-841.	1.2	11
156	Deciphering SARS-CoV-2 Virologic and Immunologic Features. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5932.	1.8	28
157	“Dark matter”™, second waves and epidemiological modelling. <i>BMJ Global Health</i> , 2020, 5, e003978.	2.0	11
158	SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 4057.	1.0	31
159	Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032032097909.	1.0	5
160	Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension. <i>Frontiers in Immunology</i> , 2020, 11, 596684.	2.2	20
161	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 568720.	1.1	5
162	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	2.2	48
163	Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?. <i>Frontiers in Immunology</i> , 2020, 11, 586765.	2.2	28

#	ARTICLE	IF	CITATIONS
164	Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 599417.	2.2	31
165	Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19. <i>Frontiers in Immunology</i> , 2020, 11, 600405.	2.2	15
166	Renal complications in coronavirus disease 2019: a systematic review. <i>Inflammation and Regeneration</i> , 2020, 40, 31.	1.5	17
167	Risk factors associated with 28-day all-cause mortality in older severe COVID-19 patients in Wuhan, China: a retrospective observational study. <i>Scientific Reports</i> , 2020, 10, 22369.	1.6	31
168	Hyperinflammation and Immune Response Generation in COVID-19. <i>NeuroImmunoModulation</i> , 2020, 27, 80-86.	0.9	41
169	Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes. <i>Frontiers in Immunology</i> , 2020, 11, 560330.	2.2	47
170	Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. <i>Frontiers in Immunology</i> , 2020, 11, 596631.	2.2	79
171	Immunocytometric analysis of COVID patients: A contribution to personalized therapy?. <i>Life Sciences</i> , 2020, 261, 118355.	2.0	32
172	Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2020, 7, 594495.	1.2	182
173	Maturation of T and B Lymphocytes in the Assessment of the Immune Status in COVID-19 Patients. <i>Cells</i> , 2020, 9, 2615.	1.8	13
174	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. <i>Pathogens</i> , 2020, 9, 1027.	1.2	20
175	Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?. <i>Frontiers in Immunology</i> , 2020, 11, 573662.	2.2	42
176	Role of SARS-CoV-2 in Altering the RNA-Binding Protein and miRNA-Directed Post-Transcriptional Regulatory Networks in Humans. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7090.	1.8	28
177	Dynamics of NK, CD8 and Tfh cell mediated the production of cytokines and antiviral antibodies in Chinese patients with moderate COVID-19. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 14270-14279.	1.6	18
178	Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility. <i>Virologica Sinica</i> , 2020, 35, 793-802.	1.2	24
179	Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients. <i>Cell Death and Disease</i> , 2020, 11, 957.	2.7	88
180	Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease. <i>Frontiers in Immunology</i> , 2020, 11, 580237.	2.2	96
181	Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. <i>Frontiers in Immunology</i> , 2020, 11, 581338.	2.2	75

#	ARTICLE	IF	CITATIONS
182	Bioinspired DNase- $\alpha$ -Coated Melanin-Like Nanospheres for Modulation of Infection-Associated NETosis Dysregulation. <i>Advanced Science</i> , 2020, 7, 2001940.	5.6	48
183	Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against COVID-19: Potential Mechanisms of Action and Future Directions. <i>Molecules</i> , 2020, 25, 5017.	1.7	70
184	Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2020, 96, 131-135.	1.5	373
185	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. <i>Vaccines</i> , 2020, 8, 224.	2.1	47
186	High-fluorescent lymphocytes are increased in patients with COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e76-e78.	1.2	12
187	COVID-19 and Cancer: a Comprehensive Review. <i>Current Oncology Reports</i> , 2020, 22, 53.	1.8	220
188	The current understanding and potential therapeutic options to combat COVID-19. <i>Life Sciences</i> , 2020, 254, 117765.	2.0	72
189	Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation. <i>Frontiers in Immunology</i> , 2020, 11, 1131.	2.2	43
190	Biochemical characterization of SARS-CoV-2 nucleocapsid protein. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 618-623.	1.0	383
191	Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 89-100.	1.5	269
192	The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102174.	0.9	62
193	Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1564-1581.	2.7	828
194	Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 1121-1128.	7.7	206
195	Drug repurposing against COVID-19: focus on anticancer agents. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 86.	3.5	57
196	More bricks in the wall against SARS-CoV-2 infection: involvement of $\gamma\delta$ T cells. <i>Cellular and Molecular Immunology</i> , 2020, 17, 771-772.	4.8	43
197	Harnessing HLA-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e185-e187.	1.2	17
198	NKG2A and COVID-19: another brick in the wall. <i>Cellular and Molecular Immunology</i> , 2020, 17, 672-674.	4.8	72
199	Cytokine storm syndrome in severe COVID-19. <i>Autoimmunity Reviews</i> , 2020, 19, 102562.	2.5	72

#	ARTICLE	IF	CITATIONS
200	An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 71, 2272-2275.	2.9	91
201	Convalescent donor SARS-CoV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date. <i>British Journal of Haematology</i> , 2020, 189, 1062-1063.	1.2	12
202	Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 667-678.	3.7	804
203	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	6.6	1,387
204	Lymphopenia in COVID-19: Therapeutic opportunities. <i>Cell Biology International</i> , 2020, 44, 1792-1797.	1.4	243
205	Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications. <i>Pharmacological Research</i> , 2020, 159, 104946.	3.1	26
207	JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 563-564.	0.9	9
208	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	2.9	95
209	A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 954-975.	1.0	14
210	Metformin use amid coronavirus disease 2019 pandemic. <i>Journal of Medical Virology</i> , 2020, 92, 2401-2402.	2.5	12
211	Can existing live vaccines prevent COVID-19?. <i>Science</i> , 2020, 368, 1187-1188.	6.0	92
212	Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors. , 2020, 2, e0141.		18
213	Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 364.	1.8	85
214	Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. <i>Pharmacotherapy</i> , 2020, 40, 843-856.	1.2	144
215	Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. <i>Clinical Immunology</i> , 2020, 217, 108509.	1.4	236
216	Dysregulation of the immune response affects the outcome of critical COVID-19 patients. <i>Journal of Medical Virology</i> , 2020, 92, 2768-2776.	2.5	41
217	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. <i>Journal of Autoimmunity</i> , 2020, 114, 102506.	3.0	248
218	The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2020, 54, 51-61.	3.2	84

#	ARTICLE	IF	CITATIONS
219	Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations. <i>Pathogens</i> , 2020, 9, 493.	1.2	79
220	NK cells: A double edge sword against SARS-CoV-2. <i>Advances in Biological Regulation</i> , 2020, 77, 100737.	1.4	77
221	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 1512.	2.2	126
222	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. <i>Pathogens</i> , 2020, 9, 426.	1.2	47
223	Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China. <i>JAMA Network Open</i> , 2020, 3, e2010895.	2.8	127
224	Novel therapeutic approaches for treatment of COVID-19. <i>Journal of Molecular Medicine</i> , 2020, 98, 789-803.	1.7	42
225	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. <i>European Journal of Cancer</i> , 2020, 135, 62-65.	1.3	32
226	The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?. <i>Frontiers in Physiology</i> , 2020, 11, 699.	1.3	50
227	Biomarkers associated with COVID-19 disease progression. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 389-399.	2.7	570
228	IL-15 immunotherapy is a viable strategy for COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2020, 54, 24-31.	3.2	38
229	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020, 26, 4201-4205.	3.2	30
230	Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1441.	2.2	515
231	Coronavirus Disease 2019 and Smoking. <i>Chest</i> , 2020, 158, 1770-1776.	0.4	20
232	Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662093350.	1.0	101
233	COVID-19 in the Cancer Patient. <i>Anesthesia and Analgesia</i> , 2020, 131, 16-23.	1.1	45
234	Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China. <i>Clinical and Translational Medicine</i> , 2020, 10, e40.	1.7	38
235	Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. <i>Protein and Cell</i> , 2020, 11, 707-722.	4.8	97
236	The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflamm-aging". <i>Inflammation Research</i> , 2020, 69, 825-839.	1.6	205

#	ARTICLE	IF	CITATIONS
237	SARS-CoV-2 infection and stem cells: Interaction and intervention. <i>Stem Cell Research</i> , 2020, 46, 101859.	0.3	27
238	The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. <i>Autoimmunity Reviews</i> , 2020, 19, 102537.	2.5	1,357
239	SARS-CoV-2 and the sympathetic immune response: Dampening inflammation with antihypertensive drugs (Clonidine and Propranolol). <i>Medical Hypotheses</i> , 2020, 144, 110039.	0.8	11
240	Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?. <i>British Dental Journal</i> , 2020, 228, 971-975.	0.3	116
241	Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation. <i>Frontiers in Immunology</i> , 2020, 11, 1062.	2.2	13
242	Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy. <i>Frontiers in Microbiology</i> , 2020, 11, 1576.	1.5	32
243	Gut-lung axis and dysbiosis in COVID-19. <i>Turkish Journal of Biology</i> , 2020, 44, 265-272.	2.1	101
244	Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19. <i>Cellular and Molecular Immunology</i> , 2020, 17, 995-997.	4.8	56
245	Detection of COVID-19 Infection from Routine Blood Exams with Machine Learning: A Feasibility Study. <i>Journal of Medical Systems</i> , 2020, 44, 135.	2.2	240
246	Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention. <i>Clinical Infectious Diseases</i> , 2022, 74, 144-148.	2.9	42
247	Cell-Mediated Immune Responses to COVID-19 Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1662.	2.2	48
248	Potential neurological effects of severe COVID-19 infection. <i>Neuroscience Research</i> , 2020, 158, 1-5.	1.0	51
249	Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. <i>Nature Communications</i> , 2020, 11, 3434.	5.8	636
250	Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: Summarizing the evidences. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1053-1060.	1.8	15
251	The Effects of Tai Chi and Qigong on Immune Responses: A Systematic Review and Meta-Analysis. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 39.	0.7	19
252	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103059.	2.0	29
253	Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. <i>Reviews in Medical Virology</i> , 2020, 30, e2123.	3.9	69
254	Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm. <i>Journal of Clinical Immunology</i> , 2020, 40, 974-976.	2.0	59

#	ARTICLE	IF	CITATIONS
256	Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. <i>Free Radical Biology and Medicine</i> , 2020, 156, 190-199.	1.3	117
257	Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives”A report of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2445-2476.	2.7	132
258	COVID-19 Hyperinflammation: What about Neutrophils?. <i>MSphere</i> , 2020, 5, .	1.3	99
259	Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2. <i>Advanced Science</i> , 2020, 7, 2001474.	5.6	14
260	Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. <i>Science Immunology</i> , 2020, 5, .	5.6	689
261	Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study. <i>Med</i> , 2020, 1, 128-138.e3.	2.2	47
262	COVID-19: towards understanding of pathogenesis. <i>Cell Research</i> , 2020, 30, 367-369.	5.7	281
263	Rethinking the role of hydroxychloroquine in the treatment of COVID-19. <i>FASEB Journal</i> , 2020, 34, 6027-6037.	0.2	110
264	Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1022.	2.2	263
265	Immunotherapies for COVID-19: lessons learned from sepsis. <i>Lancet Respiratory Medicine</i> , 2020, 8, 946-949.	5.2	111
267	COVID-19: immunopathology and its implications for therapy. <i>Nature Reviews Immunology</i> , 2020, 20, 269-270.	10.6	1,309
268	Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Chloroquine, and antiviral agents. <i>Medical Hypotheses</i> , 2020, 140, 109777.	0.8	69
269	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	2.7	87
270	Oral hygiene risk factor. <i>British Dental Journal</i> , 2020, 228, 569-569.	0.3	23
271	COVID-19 pathophysiology: A review. <i>Clinical Immunology</i> , 2020, 215, 108427.	1.4	1,414
272	Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 565-569.	1.1	298
273	Current status of potential therapeutic candidates for the COVID-19 crisis. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 59-73.	2.0	239
274	Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 442-448.	1.1	88



#	ARTICLE	IF	CITATIONS
275	Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review. <i>Journal of Medical Virology</i> , 2021, 93, 275-299.	2.5	76
276	BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. <i>Journal of Leukocyte Biology</i> , 2021, 109, 49-53.	1.5	26
277	High-dimensional single-cell analysis reveals the immune characteristics of COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L84-L98.	1.3	22
278	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. <i>International Reviews of Immunology</i> , 2021, 40, 5-53.	1.5	20
279	Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression. <i>Journal of Medical Virology</i> , 2021, 93, 1078-1098.	2.5	44
280	Coronavirus Disease 2019 (COVID-19): A Haematologist's Perspective. <i>Acta Haematologica</i> , 2021, 144, 10-23.	0.7	18
281	Immunobiology and immunotherapy of COVID-19: A clinically updated overview. <i>Journal of Cellular Physiology</i> , 2021, 236, 2519-2543.	2.0	60
282	Severe SARS-CoV-2 disease in the context of a NF- $\kappa$ B2 loss-of-function pathogenic variant. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 532-544.e1.	1.5	25
283	Re-detectable positive SARS-CoV-2 RNA tests in patients who recovered from COVID-19 with intestinal infection. <i>Protein and Cell</i> , 2021, 12, 230-235.	4.8	36
284	COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 1796-1804.	2.5	38
285	Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients. <i>Experimental Biology and Medicine</i> , 2021, 246, 5-9.	1.1	22
286	COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. <i>Postgraduate Medical Journal</i> , 2021, 97, 312-320.	0.9	444
287	Development of multi-epitope peptide-based vaccines against SARS-CoV-2. <i>Biomedical Journal</i> , 2021, 44, 18-30.	1.4	42
288	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <i>Nature Reviews Nephrology</i> , 2021, 17, 46-64.	4.1	444
289	Pathogenesis-directed therapy of 2019 novel coronavirus disease. <i>Journal of Medical Virology</i> , 2021, 93, 1320-1342.	2.5	40
290	Unique immunological profile in patients with COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 604-612.	4.8	181
291	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
292	Major reduction of NKT cells in patients with severe COVID-19 pneumonia. <i>Clinical Immunology</i> , 2021, 222, 108630.	1.4	39

#	ARTICLE	IF	CITATIONS
293	Lymphocyte subsets early predict mortality in a large series of hospitalized COVID-19 patients in Spain. <i>Clinical and Experimental Immunology</i> , 2021, 203, 424-432.	1.1	29
294	A bioinformatic approach to investigating cytokine genes and their receptor variants in relation to COVID-19 progression. <i>International Journal of Immunogenetics</i> , 2021, 48, 211-218.	0.8	17
295	Review of registered clinical trials for the treatment of COVID-19. <i>Drug Development Research</i> , 2021, 82, 474-493.	1.4	26
296	T Cells: Warriors of SARS-CoV-2 Infection. <i>Trends in Immunology</i> , 2021, 42, 18-30.	2.9	142
297	A systematic meta-analysis of immune signatures in patients with COVID-19. <i>Reviews in Medical Virology</i> , 2021, 31, e2195.	3.9	38
298	Peripheral blood inflammatory markers in predicting prognosis in patients with COVID-19. Some differences with influenza A. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23657.	0.9	27
299	Pathology of TB/COVID-19 Co-Infection: The phantom menace. <i>Tuberculosis</i> , 2021, 126, 102020.	0.8	57
300	The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. <i>Biochimie</i> , 2021, 180, 169-177.	1.3	97
301	Dysregulation of the immune response in coronavirus disease 2019. <i>Cell Biology International</i> , 2021, 45, 702-707.	1.4	41
302	Dysbiosis, malnutrition and enhanced gut-lung axis contribute to age-related respiratory diseases. <i>Ageing Research Reviews</i> , 2021, 66, 101235.	5.0	58
303	The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. <i>International Immunopharmacology</i> , 2021, 90, 107225.	1.7	75
304	Ethnicity and the relationship between covid-19 and the herpes simplex viruses. <i>Medical Hypotheses</i> , 2021, 146, 110447.	0.8	7
305	Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients. <i>Cellular and Molecular Immunology</i> , 2021, 18, 487-489.	4.8	115
306	General and Intensive Care Outcomes for Hospitalized Patients With Solid Organ Transplants With COVID-19. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 494-499.	1.3	2
307	Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. <i>International Journal of Medical Sciences</i> , 2021, 18, 29-41.	1.1	24
308	PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19. <i>Immunity</i> , 2021, 54, 44-52.e3.	6.6	184
309	Olfactory function and findings on chest computed tomography in COVID-19: is there any correlation?. <i>Acta Oto-Laryngologica</i> , 2021, 141, 293-298.	0.3	2
310	Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa588.	0.4	27

#	ARTICLE	IF	CITATIONS
311	A brief discussion of the benefit and mechanism of vitamin D supplementation on coronavirus disease 2019. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 102-107.	1.3	14
312	Asymptomatic SARS-CoV-2 infection: is it all about being refractile to innate immune sensing of viral spare-parts?â€”Clues from exotic animal reservoirs. <i>Pathogens and Disease</i> , 2021, 79, .	0.8	7
313	Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. <i>Immunity</i> , 2021, 54, 164-175.e6.	6.6	119
314	COVID-19 and Solid Organ Transplantation: A Review Article. <i>Transplantation</i> , 2021, 105, 37-55.	0.5	241
315	Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1-15.	1.9	18
316	Regulatory CD4+ and CD8+ T cells are negatively correlated with CD4+/CD8+ T cell ratios in patients acutely infected with SARS-CoV-2. <i>Journal of Leukocyte Biology</i> , 2021, 109, 91-97.	1.5	23
317	Deciphering the COVIDâ€™19 cytokine storm: Systematic review and metaâ€™analysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13429.	1.7	176
318	T cell immunobiology and cytokine storm of COVIDâ€™19. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12989.	1.3	77
319	Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 32-48.	3.2	18
320	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. <i>Cellular and Molecular Immunology</i> , 2021, 18, 936-944.	4.8	98
321	Investigation of immune cells on elimination of pulmonaryâ€™infected COVIDâ€™19 and important role of innate immunity, phagocytes. <i>Reviews in Medical Virology</i> , 2021, 31, e2158.	3.9	7
322	Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 195-203.	1.3	39
323	Lymphopenia an important immunological abnormality in patients with COVIDâ€™19: Possible mechanisms. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12967.	1.3	86
324	Tâ€™cell responses and therapies against SARSâ€™CoVâ€™2 infection. <i>Immunology</i> , 2021, 162, 30-43.	2.0	159
325	Immunopathology of Hyperinflammation in COVID-19. <i>American Journal of Pathology</i> , 2021, 191, 4-17.	1.9	372
326	Vitamin D and Covidâ€™19: From potential therapeutic effects to unanswered questions. <i>Reviews in Medical Virology</i> , 2021, 31, e2159.	3.9	27
327	COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 607583.	2.2	12
328	Management of allergic patients during severe acute respiratory syndrome coronavirus-2 pandemic. <i>Allergy Asthma &amp; Respiratory Disease</i> , 2021, 9, 115.	0.3	0

#	ARTICLE	IF	CITATIONS
329	COVID-19 pandemic as a risk factor for the reactivation of herpes viruses. <i>Epidemiology and Infection</i> , 2021, 149, e145.	1.0	17
330	Inflammatory pathways and potential therapies for COVID-19: A mini review. <i>European Journal of Inflammation</i> , 2021, 19, 205873922110029.	0.2	6
331	Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein. <i>Emerging Microbes and Infections</i> , 2021, 10, 252-255.	3.0	17
332	Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers. <i>Microorganisms</i> , 2021, 9, 159.	1.6	41
333	A possible increased risk of metamazole-associated neutropenia among COVID-19 patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2902-2906.	1.1	5
334	Immune-Based Therapy for COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 449-468.	0.8	16
335	Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19. <i>Genetics in Medicine</i> , 2021, 23, 963-967.	1.1	79
336	Role of the Immune Microenvironment in SARS-CoV-2 Infection. <i>Cell Transplantation</i> , 2021, 30, 096368972110106.	1.2	10
337	Peripheral Inflammatory Cytokines and Lymphocyte Subset Features of Deceased COVID-19 Patients. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	7
338	Clinical findings in a group of COVID-19 patients: a single-center retrospective study. <i>Annals of Translational Medicine</i> , 2021, 9, 44-44.	0.7	0
339	Potential adverse effects of coronavirus disease 2019 on the cardiovascular system. <i>Cardiology Plus</i> , 2021, 6, 30.	0.2	0
341	Herpes Zoster Co-Infection with COVID-19: A Case Series. <i>Bali Journal of Anesthesiology</i> , 2021, 5, 195.	0.0	0
342	COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients?. <i>Contributions To Nephrology</i> , 2021, 199, 1-15.	1.1	3
343	Illuminating the immunopathology of SARS-CoV-2. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 33-41.	0.7	11
344	A scoping review of the pathophysiology of COVID-19. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110480.	1.0	42
345	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
346	Does Angiotensin II Peak in Response to SARS-CoV-2?. <i>Frontiers in Immunology</i> , 2020, 11, 577875.	2.2	11
347	Protective reactive thymus hyperplasia in COVID-19 acute respiratory distress syndrome. <i>Critical Care</i> , 2021, 25, 4.	2.5	26

#	ARTICLE	IF	CITATIONS
348	High levels of soluble CD25 in COVID-19 severity suggest a divergence between anti-viral and pro-inflammatory T cell responses. <i>Clinical and Translational Immunology</i> , 2021, 10, e1251.	1.7	22
349	Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	15
350	An immunogenetic view of COVID-19. <i>Genetics and Molecular Biology</i> , 2021, 44, e20210036.	0.6	10
351	The immune response in bacterial and viral infectious diseases. <i>Medic Ro</i> , 2021, 3, 20.	0.0	0
352	COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 599736.	2.2	16
353	Emerging nanomaterials applied for tackling the COVID-19 cytokine storm. <i>Journal of Materials Chemistry B</i> , 2021, 9, 8185-8201.	2.9	4
354	The Most Significant Biomarkers and Specific Antibodies for the Early Diagnosis and Monitoring in COVID-19 Patients. <i>IFMBE Proceedings</i> , 2021, , 835-846.	0.2	0
355	NF- $\kappa$ B signalling as a pharmacological target in COVID-19: potential roles for IKK $\beta$ inhibitors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 561-567.	1.4	49
356	Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model. <i>Frontiers in Immunology</i> , 2020, 11, 621441.	2.2	43
357	Cytomegalovirus haemorrhagic enterocolitis associated with severe infection with COVID-19. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000556.	1.1	21
358	Range of Varicella Zoster Co-Infections with COVID-19, Singapore. <i>Infection and Chemotherapy</i> , 2021, 53, 391.	1.0	7
360	Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 583777.	1.6	73
361	Surviving the Rookie Virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2): The Immunopathology of a SARS-CoV2 Infection. <i>Cell Transplantation</i> , 2021, 30, 096368972199376.	1.2	2
362	Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis. <i>Immune Network</i> , 2021, 21, e1.	1.6	9
363	The Immune Response and Effectiveness of COVID-19 Therapies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1321, 115-126.	0.8	6
364	Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 598402.	2.2	25
365	COVID-19, leprosy, and neutrophils. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009019.	1.3	12
366	The Study of the Epidemiology and Clinical Features of the Novel Coronavirus (COVID-19). <i>Health Information Systems and the Advancement of Medical Practice in Developing Countries</i> , 2021, , 25-39.	0.1	7

#	ARTICLE	IF	CITATIONS
367	Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 1-22.	0.8	11
368	Immune dysregulation and system pathology in COVID-19. <i>Virulence</i> , 2021, 12, 918-936.	1.8	74
369	Immune response to COVID-19 infection: a double-edged sword. <i>Immunological Medicine</i> , 2021, 44, 187-196.	1.4	14
370	Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?. <i>Frontiers in Physiology</i> , 2020, 11, 571416.	1.3	308
371	Medicinal Plants as COVID-19 Remedy. , 2021, , 33-61.		0
372	Neuro-Oncologic Care During the COVID-19 Pandemic. , 2021, , 123-129.		0
373	Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. <i>Heliyon</i> , 2021, 7, e05990.	1.4	25
374	COVID-19 " pathogenesis and immunological findings across the clinical manifestation spectrum. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 193-198.	1.2	8
375	Atteintes pulmonaires liées à la COVID-19. <i>La Presse Médicale Formation</i> , 2021, 2, 14-24.	0.1	1
376	Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 602848.	2.2	67
377	Immunological Characteristics of Non-Intensive Care Hospitalized COVID-19 Patients: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2021, 10, 849.	1.0	6
378	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 629933.	1.1	43
379	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. <i>Nature Communications</i> , 2021, 12, 1260.	5.8	115
380	Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF- $\kappa$ B: A Systematic Review. <i>Viruses</i> , 2021, 13, 378.	1.5	14
381	T cell counts and IL-6 concentration in blood of North African COVID-19 patients are two independent prognostic factors for severe disease and death. <i>Journal of Leukocyte Biology</i> , 2021, 111, 269-281.	1.5	25
382	SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. , 2021, 9, e001694.		23
383	COVID-19 illness and autoimmune diseases: recent insights. <i>Inflammation Research</i> , 2021, 70, 407-428.	1.6	13
384	T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 624483.	1.8	110

#	ARTICLE	IF	CITATIONS
385	COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. <i>FASEB Journal</i> , 2021, 35, e21409.	0.2	71
386	Reduced Expression of Autophagy Markers and Expansion of Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 614599.	2.2	50
387	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. <i>Frontiers in Medicine</i> , 2021, 8, 604087.	1.2	1
388	COVID-19-associated liver injury: from bedside to bench. <i>Journal of Gastroenterology</i> , 2021, 56, 218-230.	2.3	39
389	CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. <i>Cell Stress and Chaperones</i> , 2021, 26, 515-525.	1.2	15
390	Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1255-1268.	1.8	23
391	The Relevance of a Physical Active Lifestyle and Physical Fitness on Immune Defense: Mitigating Disease Burden, With Focus on COVID-19 Consequences. <i>Frontiers in Immunology</i> , 2021, 12, 587146.	2.2	72
392	Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. <i>Cell Host and Microbe</i> , 2021, 29, 222-235.e4.	5.1	145
393	SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2356.	1.8	13
394	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. <i>International Reviews of Immunology</i> , 2022, 41, 171-206.	1.5	30
395	Calprotectin, an Emerging Biomarker of Interest in COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 775.	1.0	33
398	SARS-CoV-2: phylogenetic origins, pathogenesis, modes of transmission, and the potential role of nanotechnology. <i>VirusDisease</i> , 2021, 32, 1-12.	1.0	28
399	Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 58.	7.1	178
400	The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked Agammaglobulinemia. <i>American Journal of Case Reports</i> , 2021, 22, e929447.	0.3	12
401	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 574425.	2.2	38
402	COVID-19 and pregnancy: are they friends or enemies?. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2021, 42, 57-62.	0.3	3
403	An overview of COVID-19 in people with diabetes: Pathophysiology and considerations in the inpatient setting. <i>Diabetic Medicine</i> , 2021, 38, e14509.	1.2	24
404	Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 2917-2942.	1.4	29

#	ARTICLE	IF	CITATIONS
405	The effect of age on the clinical and immune characteristics of critically ill patients with COVID-19: A preliminary report. PLoS ONE, 2021, 16, e0248675.	1.1	19
406	COVID-19 Therapy: Could a Copper Derivative of Chlorophyll a Be Used to Treat Lymphopenia Associated With Severe Symptoms of SARS-CoV-2 Infection?. Frontiers in Medicine, 2021, 8, 620175.	1.2	5
407	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. ImmunoTargets and Therapy, 2021, Volume 10, 63-85.	2.7	40
408	Early identification of patients with severe COVID-19 at increased risk of in-hospital death: a multicenter case-control study in Wuhan. Journal of Thoracic Disease, 2021, 13, 1380-1395.	0.6	8
409	Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients. Current Pharmaceutical Design, 2021, 27, 866-875.	0.9	20
411	Review of studies of severe acute respiratory syndrome related coronavirusâ€“2 pathogenesis in human organoid models. Reviews in Medical Virology, 2021, 31, e2227.	3.9	10
412	Common laboratory tests as indicators of COVID-19 severity on admission at high altitude: a single-center retrospective study in Quito (ECUADOR). Clinical Chemistry and Laboratory Medicine, 2021, 59, e326-e329.	1.4	11
413	Herpes zoster following inactivated COVIDâ€“19 vaccine: A coexistence or coincidence?. Journal of Cosmetic Dermatology, 2021, 20, 1566-1567.	0.8	106
414	Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines. Microorganisms, 2021, 9, 683.	1.6	25
415	Nanotechnology to the Rescue: Treatment Perspective for the Immune Dysregulation Observed in COVID-19. Frontiers in Nanotechnology, 2021, 3, .	2.4	4
417	Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19. Journal of Molecular Cell Biology, 2021, 13, 197-209.	1.5	17
418	Platelet parameters and leukocyte morphology is altered in COVID-19 patients compared to non-COVID-19 patients with similar symptomatology. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 213-217.	0.6	21
419	Immune memory in convalescent patients with asymptomatic or mild COVID-19. Cell Discovery, 2021, 7, 18.	3.1	35
420	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. Biology, 2021, 10, 208.	1.3	16
421	COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. Journal of Infection, 2021, 82, 329-338.	1.7	150
422	Lung Protection vs. Infection Resolution: Interleukin 10 Suspected of Double-Dealing in COVID-19. Frontiers in Immunology, 2021, 12, 602130.	2.2	21
423	Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. Fundamental Research, 2021, 1, 124-130.	1.6	5
424	Immune Response Failure in Paucisymptomatic Long-Standing SARS-CoV-2 Spreaders. Clinics and Practice, 2021, 11, 151-161.	0.6	2



#	ARTICLE	IF	CITATIONS
425	The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients. <i>Medicina (Lithuania)</i> , 2021, 57, 257.	0.8	8
426	IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection. <i>Communications Biology</i> , 2021, 4, 290.	2.0	74
427	Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2. <i>Frontiers of Medicine</i> , 2021, 15, 638-643.	1.5	9
428	Nexus between COVID-19 and periodontal disease. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110026.	0.4	20
429	COVID-19 hospitalization rates rise exponentially with age, inversely proportional to thymic T-cell production. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20200982.	1.5	31
430	Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. <i>Journal of Autoimmunity</i> , 2021, 118, 102596.	3.0	27
432	Monitoring peripheral neutrophil and T-lymphocyte subsets could assist in differentiating the severity and disease progression of coronavirus disease 2019. <i>Aging</i> , 2021, 13, 7723-7732.	1.4	4
433	Clinical characteristics of older patients with COVID-19: a systematic review of case reports. <i>Dementia E Neuropsychologia</i> , 2021, 15, 1-15.	0.3	9
434	The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 37-46.	0.2	5
436	Proteomic investigation reveals dominant alterations of neutrophil degranulation and mRNA translation pathways in patients with COVID-19. <i>iScience</i> , 2021, 24, 102135.	1.9	29
439	The association between vitamin D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital. <i>European Journal of Pediatrics</i> , 2021, 180, 2699-2705.	1.3	31
440	Profiles of Peripheral Immune Cells of Uncomplicated COVID-19 Cases with Distinct Viral RNA Shedding Periods. <i>Viruses</i> , 2021, 13, 514.	1.5	1
441	The Weight of Obesity in Immunity from Influenza to COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 638852.	1.8	24
442	Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3004.	1.8	25
443	COVID-19â€™A Theory of Autoimmunity Against ACE-2 Explained. <i>Frontiers in Immunology</i> , 2021, 12, 582166.	2.2	41
444	Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. <i>Frontiers in Immunology</i> , 2021, 12, 651728.	2.2	6
445	Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 109-121.	1.8	41
446	T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 655934.	2.2	50

#	ARTICLE	IF	CITATIONS
447	Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. <i>Immunity</i> , 2021, 54, 557-570.e5.	6.6	153
448	Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3059.	1.8	36
449	Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. <i>Nature Communications</i> , 2021, 12, 1724.	5.8	97
450	Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. <i>PLoS ONE</i> , 2021, 16, e0247640.	1.1	53
451	Impact of SARS-CoV-2 on the clinical outcomes and placental pathology of pregnant women and their infants: A systematic review. <i>Heliyon</i> , 2021, 7, e06393.	1.4	24
452	COVID-19 and Coronary Heart Disease. <i>Encyclopedia</i> , 2021, 1, 340-349.	2.4	8
453	Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1906.	1.7	6
454	Cellular Immune Response to COVID-19 and Potential Immune Modulators. <i>Frontiers in Immunology</i> , 2021, 12, 646333.	2.2	47
455	COVID-19 and Pregnancy: Vertical Transmission and Inflammation Impact on Newborns. <i>Vaccines</i> , 2021, 9, 391.	2.1	22
456	Utilization of C-Reactive Protein Test as a Predictor of Lung Injury in Patients with Coronavirus Disease 2019. <i>Laboratory Medicine Online</i> , 2021, 11, 81-87.	0.0	0
457	Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China. <i>World Journal of Clinical Cases</i> , 2021, 9, 2205-2217.	0.3	3
458	TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVID-19 patients. <i>Journal of Leukocyte Biology</i> , 2021, , .	1.5	5
459	Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. <i>Critical Care</i> , 2021, 25, 140.	2.5	27
460	Clinical characteristics of Egyptian male patients with COVID-19 acute respiratory distress syndrome. <i>PLoS ONE</i> , 2021, 16, e0249346.	1.1	62
461	Advances in immunotherapy for COVID-19: A comprehensive review. <i>International Immunopharmacology</i> , 2021, 93, 107409.	1.7	16
462	Characterizing the immune responses of those who survived or succumbed to COVID-19: Can immunological signatures predict outcome?. <i>Cytokine</i> , 2021, 140, 155439.	1.4	18
463	Obesity and its impact on COVID-19. <i>Journal of Molecular Medicine</i> , 2021, 99, 899-915.	1.7	41
464	Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients. <i>Microbial Pathogenesis</i> , 2021, 153, 104779.	1.3	19

#	ARTICLE	IF	CITATIONS
465	Relationship of COVID-19 pathogenesis for periodontal medicine research. Part I: Pathogenesis of COVID-19. <i>Research, Society and Development</i> , 2021, 10, e1910513729.	0.0	0
466	Potential Role of the Galectin-9/TIM-3 Axis in the Disparate Progression of SARS-CoV-2 in a Married Couple: A Case Report. <i>Biomedicine Hub</i> , 2021, 6, 48-58.	0.4	12
467	Herpes Simplex Keratitis in Patients with SARS-CoV-2 Infection: A Series of Five Cases. <i>Medicina (Lithuania)</i> , 2021, 57, 412.	0.8	22
468	COVID-IRS: A novel predictive score for risk of invasive mechanical ventilation in patients with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0248357.	1.1	21
469	Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: A multi-center study. <i>PLoS ONE</i> , 2021, 16, e0249668.	1.1	47
470	Feasibility Assessment of an Encapsulated Longevity Spinach ( <i>Gynura procumbens</i> L.) Extract Plant in Indonesia. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4093.	1.3	5
471	MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity. <i>Immunologic Research</i> , 2021, 69, 117-128.	1.3	49
472	Uremia-Associated Immunological Aging and Severity of COVID-19 Infection. <i>Frontiers in Medicine</i> , 2021, 8, 675573.	1.2	12
473	Maternal natural killer cells at the intersection between reproduction and mucosal immunity. <i>Mucosal Immunology</i> , 2021, 14, 991-1005.	2.7	20
474	Increased Bâ€cell activity with consumption of activated monocytes in severe COVIDâ€19 patients. <i>European Journal of Immunology</i> , 2021, 51, 1449-1460.	1.6	10
475	Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies. <i>Journal of Translational Medicine</i> , 2021, 19, 139.	1.8	13
476	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. <i>Cancer Discovery</i> , 2021, 11, 1336-1344.	7.7	20
477	Could Antigen Presenting Cells Represent a Protective Element during SARS-CoV-2 Infection in Children?. <i>Pathogens</i> , 2021, 10, 476.	1.2	8
478	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. <i>Modern Pathology</i> , 2021, 34, 1456-1467.	2.9	184
479	Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 224, 229-240.	1.9	27
480	COVID-19 and the human innate immune system. <i>Cell</i> , 2021, 184, 1671-1692.	13.5	524
481	A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). <i>Immunologic Research</i> , 2021, 69, 213-224.	1.3	27
482	The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. <i>Modern Pathology</i> , 2021, 34, 1444-1455.	2.9	41

#	ARTICLE	IF	CITATIONS
483	Heparin binding protein in severe COVID-19”A prospective observational cohort study. PLoS ONE, 2021, 16, e0249570.	1.1	12
484	Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection. FASEB Journal, 2021, 35, e21577.	0.2	13
485	Features of HLA class I expression and its clinical relevance in SARS-CoV-2: What do we know so far?. Reviews in Medical Virology, 2021, 31, e2236.	3.9	9
486	Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures. Biosensors and Bioelectronics, 2021, 177, 112969.	5.3	22
487	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microbial Cell Factories, 2021, 20, 88.	1.9	37
488	Longitudinal Peripheral Blood Transcriptional Analysis Reveals Molecular Signatures of Disease Progression in COVID-19 Patients. Journal of Immunology, 2021, 206, 2146-2159.	0.4	25
489	A useful and sensitive marker in the prediction of COVID-19 and disease severity: Thiol. Free Radical Biology and Medicine, 2021, 166, 11-17.	1.3	23
490	Immune Profile in Patients With COVID-19: Lymphocytes Exhaustion Markers in Relationship to Clinical Outcome. Frontiers in Cellular and Infection Microbiology, 2021, 11, 646688.	1.8	47
491	COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes. European Journal of Pharmacology, 2021, 896, 173930.	1.7	23
492	Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra. International Immunopharmacology, 2021, 93, 107407.	1.7	16
493	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. PLoS Pathogens, 2021, 17, e1009448.	2.1	43
494	Accelerated Progression of Disseminated Coccidioidomycosis Following SARS-CoV-2 Infection: A Case Report. Military Medicine, 2021, 186, 1254-1256.	0.4	17
495	Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. International Immunopharmacology, 2021, 93, 107364.	1.7	54
496	The Mechanisms and Animal Models of SARS-CoV-2 Infection. Frontiers in Cell and Developmental Biology, 2021, 9, 578825.	1.8	20
497	A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis. Biochemistry and Cell Biology, 2021, 99, 173-194.	0.9	3
498	COVID-19 in Immunosuppressed Children. Frontiers in Pediatrics, 2021, 9, 629240.	0.9	30
499	Tai Chi to Preserve General Health of Elderly during the COVID-19 Pandemic. Ulum Islamiyyah, 0, , 57-76.	0.1	0
501	Spectrum of Immunopathogenesis in Coronavirus Disease 2019 (COVID-19): An Updated Review. International Journal of Pharmacology, 2021, 17, 358-369.	0.1	0

#	ARTICLE	IF	CITATIONS
502	The initial infectious dose of SARS-CoV-2 and the severity of the disease: possible impact on the incubation period. <i>Future Virology</i> , 2021, 16, 369-373.	0.9	3
503	Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. <i>Cell Discovery</i> , 2021, 7, 37.	3.1	11
504	Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives. <i>Life Sciences</i> , 2021, 272, 119251.	2.0	32
505	Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 659018.	2.2	14
506	Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement. <i>Biomolecules</i> , 2021, 11, 787.	1.8	14
507	Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses. <i>Pathogens</i> , 2021, 10, 565.	1.2	57
508	Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. <i>Frontiers in Immunology</i> , 2021, 12, 665329.	2.2	26
509	Analysis of COVID-19 on Diagnosis, Vaccine, Treatment, and Pathogenesis with Clinical Scenarios. <i>Clinics and Practice</i> , 2021, 11, 309-321.	0.6	6
510	Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study. <i>Clinical Immunology</i> , 2021, 226, 108712.	1.4	19
511	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. <i>Molecular Cancer</i> , 2021, 20, 76.	7.9	42
512	SARS-CoV-2-Induced Gut Microbiome Dysbiosis: Implications for Colorectal Cancer. <i>Cancers</i> , 2021, 13, 2676.	1.7	21
513	COVID-19 and central nervous system interplay: A big picture beyond clinical manifestation. <i>Journal of Biosciences</i> , 2021, 46, 1.	0.5	9
514	Identification of PBMC-based molecular signature associational with COVID-19 disease severity. <i>Heliyon</i> , 2021, 7, e06866.	1.4	19
515	The Symptoms and Clinical Manifestations Observed in COVID-19 Patients/Long COVID-19 Symptoms that Parallel <i>Toxoplasma gondii</i> Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 513-516.	2.1	13
516	Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. <i>Infectious Diseases of Poverty</i> , 2021, 10, 71.	1.5	42
517	Contribution of STAT3 to the pathogenesis of COVID-19. <i>Microbial Pathogenesis</i> , 2021, 154, 104836.	1.3	63
518	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	5.6	455
519	The interplay between the immune system and SARS-CoV-2 in COVID-19 patients. <i>Archives of Virology</i> , 2021, 166, 2109-2117.	0.9	7

#	ARTICLE	IF	CITATIONS
520	Lymphopenia in COVID-19: T Cells-Based Therapeutic Opportunities. <i>Vaccines</i> , 2021, 9, 562.	2.1	5
521	Tranilast: a potential anti-inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 247-258.	1.1	25
522	Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. <i>Nature Communications</i> , 2021, 12, 2593.	5.8	94
523	Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. <i>Frontiers in Immunology</i> , 2021, 12, 666163.	2.2	27
524	A High Neutrophil-Lymphocyte Ratio Is Associated With Increased Morbidity and Mortality in Patients With Coronavirus Disease 2019. , 2021, 3, e0444.		13
525	Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity. <i>Journal of Infectious Diseases</i> , 2021, 224, 777-782.	1.9	26
526	Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. <i>Npj Vaccines</i> , 2021, 6, 71.	2.9	23
527	Herpes zoster emergence following mRNA COVID-19 vaccine. <i>Journal of Medical Virology</i> , 2021, 93, 5231-5232.	2.5	75
528	Dynamic causal modelling of immune heterogeneity. <i>Scientific Reports</i> , 2021, 11, 11400.	1.6	3
529	Case Report: Successful Response to Intravenous Immunoglobulin and Steroid Pulses in a Renal Transplant Recipient With Severe Covid-19 Disease and Associated Acute Allograft Failure. <i>Frontiers in Immunology</i> , 2021, 12, 671013.	2.2	5
530	Immunomodulatory and antioxidant activity from Indonesian anti-degenerative herbs water extract. <i>Journal of Complementary and Integrative Medicine</i> , 2021, .	0.4	1
531	Risk Factors for COVID-19 in Patients with Hypertension. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2021, 2021, 1-9.	0.7	6
532	The Many Faces of Innate Immunity in SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 596.	2.1	10
533	Hemophagocytic histiocytosis in severe SARS-CoV-2 infection: A bone marrow study. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1291-1301.	0.7	13
534	The role of estradiol in the immune response against COVID-19. <i>Hormones</i> , 2021, 20, 657-667.	0.9	21
535	Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?. <i>Frontiers in Immunology</i> , 2021, 12, 677008.	2.2	98
536	Viral coinfections in COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 5310-5322.	2.5	53
537	Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7017.	1.8	43

#	ARTICLE	IF	CITATIONS
538	Duration of post-COVID-19 symptoms are associated with sustained SARS-CoV-2 specific immune responses. JCI Insight, 2021, 6, .	2.3	31
539	The Immunopathobiology of SARS-CoV-2 Infection. FEMS Microbiology Reviews, 2021, 45, .	3.9	9
540	Lymphocyteâ€œmonocyteâ€œneutrophil index: a predictor of severity of coronavirus disease 2019 patients produced by sparse principal component analysis. Virology Journal, 2021, 18, 115.	1.4	5
541	Vitamin D and Exercise Are Major Determinants of Natural Killer Cell Activity, Which Is Age- and Gender-Specific. Frontiers in Immunology, 2021, 12, 594356.	2.2	16
542	Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application. Clinical Immunology, 2021, 227, 108727.	1.4	39
543	Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection. Nature Communications, 2021, 12, 3501.	5.8	40
544	Clinical Significance of Micronutrient Supplementation in Critically Ill COVID-19 Patients with Severe ARDS. Nutrients, 2021, 13, 2113.	1.7	36
545	Immune characterization of a Colombian family cluster with SARS-CoV-2 infection. Biomedica, 2021, 41, 86-102.	0.3	2
546	Baricitinib: From Rheumatoid Arthritis to COVIDâ€œ19. Journal of Clinical Pharmacology, 2021, 61, 1274-1285.	1.0	40
547	Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Frontiers in Immunology, 2021, 12, 686029.	2.2	152
548	Endothelial Senescence and Chronic Fatigue Syndrome, a COVID-19 Based Hypothesis. Frontiers in Cellular Neuroscience, 2021, 15, 673217.	1.8	21
549	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. , 2021, 9, e002630.		76
550	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). Sovremennyye Tehnologii V Medicine, 2021, 13, 81.	0.4	4
551	PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses. Biomaterials, 2021, 273, 120827.	5.7	28
552	Lung-Centric Inflammation of COVID-19: Potential Modulation by Vitamin D. Nutrients, 2021, 13, 2216.	1.7	15
553	Vitamin D supplementation and Covidâ€œ19 outcomes: A systematic review, metaâ€œanalysis and metaâ€œregression. Reviews in Medical Virology, 2022, 32, e2269.	3.9	28
554	Phenotypes and Functions of SARS-CoV-2-Reactive T Cells. Molecules and Cells, 2021, 44, 401-407.	1.0	16
555	An overview of some potential immunotherapeutic options against COVID-19. International Immunopharmacology, 2021, 95, 107516.	1.7	7

#	ARTICLE	IF	CITATIONS
556	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. <i>Angiogenesis</i> , 2021, 24, 755-788.	3.7	114
557	Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2. <i>Microorganisms</i> , 2021, 9, 1303.	1.6	2
558	Metabolic reprogramming and immune regulation in viral diseases. <i>Reviews in Medical Virology</i> , 2022, 32, e2268.	3.9	7
560	Impact of age and gender on lymphocyte subset counts in patients with COVID-19. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 127-135.	1.1	10
563	Efficacy of phytochemicals as immunomodulators in managing COVID-19: a comprehensive view. <i>VirusDisease</i> , 2021, 32, 435-445.	1.0	7
564	Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. <i>Frontiers in Microbiology</i> , 2021, 12, 698169.	1.5	512
566	AI-guided discovery of the invariant host response to viral pandemics. <i>EBioMedicine</i> , 2021, 68, 103390.	2.7	37
567	The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. <i>International Immunopharmacology</i> , 2021, 95, 107586.	1.7	26
568	SARS-CoV-2 Proteins Induce Endotoxin Tolerance Hallmarks: A Demonstration in Patients with COVID-19. <i>Journal of Immunology</i> , 2021, 207, 162-174.	0.4	6
569	Use of nanotechnology in combating coronavirus. <i>3 Biotech</i> , 2021, 11, 358.	1.1	6
570	The Quality of SARS-CoV-2-Specific T Cell Functions Differs in Patients with Mild/Moderate versus Severe Disease, and T Cells Expressing Coinhibitory Receptors Are Highly Activated. <i>Journal of Immunology</i> , 2021, 207, 1099-1111.	0.4	34
571	A Rare Case of Herpes Zoster in an Adult Patient Recovered From Symptomatic Reinfection of COVID-19. <i>Cureus</i> , 2021, 13, e16274.	0.2	6
572	Ibuprofen and COVID-19 disease: separating the myths from facts. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 979-983.	1.0	18
573	Pharmacological Effects of Selected Medicinal Plants and Vitamins Against COVID-19. , 2021, 7, .		4
575	The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1784-1789.	2.8	54
576	A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine. <i>Medical Hypotheses</i> , 2021, 152, 110619.	0.8	1
577	Significance of peripheral blood indexes in differential diagnoses of SARS-CoV-2 and New Bunia virus. <i>Scientific Reports</i> , 2021, 11, 14094.	1.6	3
578	Physical activity and exercise as an essential medical strategy for the COVID-19 pandemic and beyond. <i>Experimental Biology and Medicine</i> , 2021, 246, 2324-2331.	1.1	2



#	ARTICLE	IF	CITATIONS
579	Does chronic inflammation cause acute inflammation to spiral into hyperinflammation in a manner modulated by diet and the gut microbiome, in severe COVID-19? <i>BioEssays</i> , 2021, 43, 2000211.	1.2	3
580	Decreased Serum Selenium Levels of COVID-19 Patients in Comparison with Healthy Individuals. <i>Biological Trace Element Research</i> , 2022, 200, 1562-1567.	1.9	26
581	Protecting persons at-risk of viral hepatitis and alcohol-related liver disease during the pandemic and beyond: mitigating the impact of coronavirus disease 2019 on liver health. <i>Journal of Global Health Reports</i> , 0, , .	1.0	1
582	Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. <i>Cell Reports</i> , 2021, 36, 109432.	2.9	24
583	Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	7
584	Interplay between Neutrophils, NETs and T-Cells in SARS-CoV-2 Infection – A Missing Piece of the Puzzle in the COVID-19 Pathogenesis?. <i>Cells</i> , 2021, 10, 1817.	1.8	8
585	Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7850.	1.8	33
586	Insights into Innate Immune Response Against SARS-CoV-2 Infection. <i>Romanian Journal of Laboratory Medicine</i> , 2021, 29, 255-269.	0.1	3
587	The Potential Role of an Aberrant Mucosal Immune Response to SARS-CoV-2 in the Pathogenesis of IgA Nephropathy. <i>Pathogens</i> , 2021, 10, 881.	1.2	10
588	Will a little change do you good? A putative role of polymorphisms in COVID-19. <i>Immunology Letters</i> , 2021, 235, 9-14.	1.1	10
589	Deep learning identifies antigenic determinants of severe SARS-CoV-2 infection within T-cell repertoires. <i>Scientific Reports</i> , 2021, 11, 14275.	1.6	10
590	Prolonged humoral and cellular immunity in COVID-19-recovered patients. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 4010-4015.	1.8	12
591	The role of natural killer cells in liver inflammation. <i>Seminars in Immunopathology</i> , 2021, 43, 519-533.	2.8	19
592	Immune cell profiling and antibody responses in patients with COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 646.	1.3	17
593	Analysis of the dynamic relationship between immune profiles and the clinical features of patients with COVID-19. <i>Annals of Translational Medicine</i> , 2021, 9, 1118-1118.	0.7	3
594	Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. <i>Journal of Advanced Research</i> , 2021, 31, 49-60.	4.4	27
595	Case Report: Analysis of Inflammatory Cytokines IL-6, CCL2/MCP1, CCL5/RANTES, CXCL9/MIG, and CXCL10/IP10 in a Cystic Fibrosis Patient Cohort During the First Wave of the COVID-19 Pandemic. <i>Frontiers in Pediatrics</i> , 2021, 9, 645063.	0.9	3
596	A role for T cell exhaustion in Long COVID-19 and severe outcomes for several categories of COVID-19 patients. <i>Journal of Neuroscience Research</i> , 2021, 99, 2367-2376.	1.3	19

#	ARTICLE	IF	CITATIONS
597	Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	3
598	Characterization of low-density granulocytes in COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009721.	2.1	51
599	Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. <i>Drug Discovery Today</i> , 2021, 26, 2619-2636.	3.2	143
601	Comparative Characterization and Risk Stratification of Asymptomatic and Presymptomatic Patients With COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 700449.	2.2	2
602	Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5953-5976.	2.4	19
605	Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19. <i>Heliyon</i> , 2021, 7, e07635.	1.4	9
606	Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2. <i>Life Sciences</i> , 2021, 277, 119503.	2.0	17
607	Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. <i>Immunity</i> , 2021, 54, 1578-1593.e5.	6.6	75
608	The signal pathways and treatment of cytokine storm in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 255.	7.1	355
609	Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0255608.	1.1	34
611	Potential Physiological and Cellular Mechanisms of Exercise That Decrease the Risk of Severe Complications and Mortality Following SARS-CoV-2 Infection. <i>Sports</i> , 2021, 9, 121.	0.7	4
613	Innate lymphoid cells (ILC) in SARS-CoV-2 infection. <i>Molecular Aspects of Medicine</i> , 2021, 80, 101008.	2.7	10
614	Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches. <i>Molecular Biology Reports</i> , 2021, 48, 6513-6524.	1.0	6
615	Cardiovascular Disease Complicating COVID-19 in the Elderly. <i>Medicina (Lithuania)</i> , 2021, 57, 833.	0.8	9
616	Convalescent COVID-19 Patients Without Comorbidities Display Similar Immunophenotypes Over Time Despite Divergent Disease Severities. <i>Frontiers in Immunology</i> , 2021, 12, 601080.	2.2	7
617	Activation or exhaustion of CD8+ T cells in patients with COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2325-2333.	4.8	106
618	Severe acute respiratory syndrome coronavirus 2 targeted antibodies cocktail and B cell receptor interplay: interventions to trigger vaccine development. <i>Exploration of Immunology</i> , 0, , .	1.7	0
619	OMIP 078: A 31-parameter panel for comprehensive immunophenotyping of multiple immune cells in human peripheral blood mononuclear cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 893-898.	1.1	10

#	ARTICLE	IF	CITATIONS
620	SARS-CoV-2 infection initiates interleukin-17-enriched transcriptional response in different cells from multiple organs. <i>Scientific Reports</i> , 2021, 11, 16814.	1.6	43
621	Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. <i>International Immunopharmacology</i> , 2021, 97, 107828.	1.7	21
622	The role of vitamin D in the age of COVID-19: A systematic review and meta-analysis. <i>International Journal of Clinical Practice</i> , 2021, 75, e14675.	0.8	68
623	Asymptomatic COVID-19 Individuals Tend to Establish Relatively Balanced Innate and Adaptive Immune Responses. <i>Pathogens</i> , 2021, 10, 1105.	1.2	8
624	Inflammation, a common mechanism in frailty and COVID19 , and stem cells as a therapeutic approach. <i>Stem Cells Translational Medicine</i> , 2021, 10, 1482-1490.	1.6	8
625	Neuropathy in COVID-19 associated with dysbiosis-related inflammation. <i>Turkish Journal of Biology</i> , 2021, 45, 390-403.	2.1	6
626	Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19. <i>Journal of Infection and Public Health</i> , 2021, 14, 1106-1119.	1.9	4
627	Immunological parameters associated with the severity of COVID-19 pneumonia in kidney transplant recipients. <i>International Urology and Nephrology</i> , 2021, , 1.	0.6	1
628	A Systematic Review of Characteristics Associated with COVID-19 in Children with Typical Presentation and with Multisystem Inflammatory Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8269.	1.2	17
629	Evidence of Long-Lasting Humoral and Cellular Immunity against SARS-CoV-2 Even in Elderly COVID-19 Convalescents Showing a Mild to Moderate Disease Progression. <i>Life</i> , 2021, 11, 805.	1.1	7
630	Immunological and inflammatory profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. <i>International Immunopharmacology</i> , 2021, 97, 107685.	1.7	22
631	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. <i>Cytokine</i> , 2021, 144, 155593.	1.4	61
632	Immunometabolic signatures predict risk of progression to sepsis in COVID-19. <i>PLoS ONE</i> , 2021, 16, e0256784.	1.1	22
633	COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators. <i>Immunologic Research</i> , 2021, 69, 457-460.	1.3	5
634	Interferon- gamma-induced protein-10 (IP-10) serum level and natural killer cell count as predictive factors for the severity of COVID-19. <i>Microbes and Infectious Diseases</i> , 2021, .	0.0	1
636	Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates. <i>Frontiers in Microbiology</i> , 2021, 12, 626553.	1.5	90
637	Severe pediatric COVID-19 with acute respiratory distress syndrome: a narrative review. <i>Pediatric Medicine</i> , 0, 4, 27-27.	1.1	1
638	NK Cell Subpopulations and Receptor Expression in Recovering SARS-CoV-2 Infection. <i>Molecular Neurobiology</i> , 2021, 58, 6111-6120.	1.9	10

#	ARTICLE	IF	CITATIONS
639	Secondary infections in critically ill patients with COVID-19. <i>Critical Care</i> , 2021, 25, 317.	2.5	31
640	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. <i>Frontiers in Immunology</i> , 2021, 12, 719023.	2.2	28
641	Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients. <i>Antioxidants</i> , 2021, 10, 1440.	2.2	28
643	Maslow's theory for preventive healthcare in India – a content analysis approach. <i>International Journal of Pharmaceutical and Healthcare Marketing</i> , 2022, 16, 40-54.	0.7	0
644	Are Host Defense Peptides and Their Derivatives Ready to be Part of the Treatment of the Next Coronavirus Pandemic?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2021, 69, 25.	1.0	3
645	The role of type I interferon in the treatment of COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 63-81.	2.5	52
646	Lymphopenia in Covid-19: A single center retrospective study of 589 cases. <i>Annals of Medicine and Surgery</i> , 2021, 69, 102816.	0.5	27
647	Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. <i>Human Immunology</i> , 2022, 83, 86-98.	1.2	37
648	A Chinese host genetic study discovered IFNs and causality of laboratory traits on COVID-19 severity. <i>IScience</i> , 2021, 24, 103186.	1.9	10
649	Perioperative use of intra-articular steroids during the COVID-19 pandemic. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2021, , 1.	0.6	0
650	Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 796.e1-796.e7.	0.6	42
651	Association of HLA genotypes, ABO blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19. <i>European Journal of Medical Research</i> , 2021, 26, 107.	0.9	12
652	Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?. <i>Frontiers in Medicine</i> , 2021, 8, 663708.	1.2	13
653	Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19. <i>Molecules</i> , 2021, 26, 5803.	1.7	13
654	Cellular Immunotherapy and the Lung. <i>Vaccines</i> , 2021, 9, 1018.	2.1	5
655	CD8+PD-L1+CXCR3+ polyfunctional T cell abundances are associated with survival in critical SARS-CoV-2-infected patients. <i>JCI Insight</i> , 2021, 6, .	2.3	16
656	Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019. <i>Intensive Care Medicine Experimental</i> , 2021, 9, 45.	0.9	5
658	Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients. <i>Molecular Immunology</i> , 2021, 137, 221-227.	1.0	6

#	ARTICLE	IF	CITATIONS
659	Immunological Profiling of COVID-19 Patients with Pulmonary Sequelae. <i>MBio</i> , 2021, 12, e0159921.	1.8	16
660	Microbial Metabolites: The Emerging Hotspot of Antiviral Compounds as Potential Candidates to Avert Viral Pandemic Alike COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 732256.	1.6	15
661	Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU. <i>Frontiers in Immunology</i> , 2021, 12, 742631.	2.2	23
662	LOX-1-Expressing Immature Neutrophils Identify Critically-Ill COVID-19 Patients at Risk of Thrombotic Complications. <i>Frontiers in Immunology</i> , 2021, 12, 752612.	2.2	14
663	Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study. <i>Clinical and Experimental Medicine</i> , 2022, 22, 465-476.	1.9	7
664	Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13101.	1.3	16
665	An association between immune status and chest CT scores in COVID-19 patients. <i>International Journal of Clinical Practice</i> , 2021, 75, e14767.	0.8	3
666	Biomarkers of severe COVID-19 pneumonia on admission using data-mining powered by common laboratory blood tests-datasets. <i>Computers in Biology and Medicine</i> , 2021, 136, 104738.	3.9	10
667	Rheumatological complications of Covid 19. <i>Autoimmunity Reviews</i> , 2021, 20, 102883.	2.5	73
668	The Effects of COVID-19 on the Placenta During Pregnancy. <i>Frontiers in Immunology</i> , 2021, 12, 743022.	2.2	39
669	Cytometric analysis of patients with COVID-19: what is changed in the second wave?. <i>Journal of Translational Medicine</i> , 2021, 19, 403.	1.8	5
670	CSGNet: An Explainable Deep Learning Framework for COVID-19 Detection. <i>Diagnostics</i> , 2021, 11, 1712.	1.3	7
671	COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF- $\kappa$ B Pathway. <i>Viruses</i> , 2021, 13, 1887.	1.5	12
672	Otoneurological presentations of COVID-19. <i>BMJ Case Reports</i> , 2021, 14, e241893.	0.2	2
673	Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 725606.	1.8	8
674	Mild and Asymptomatic COVID-19 Convalescents Present Long-Term Endotype of Immunosuppression Associated With Neutrophil Subsets Possessing Regulatory Functions. <i>Frontiers in Immunology</i> , 2021, 12, 748097.	2.2	22
675	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. <i>Viral Immunology</i> , 2021, 34, 639-645.	0.6	13
676	TRINITY OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2: ORIGIN, GENOTYPE, PHENOTYPE, AND IMMUNE RESPONSE IN CORONAVIRUS DISEASE-2019. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 28-36.	0.3	1

#	ARTICLE	IF	CITATIONS
677	Neutrophil Maturation, Reactivity and Granularity Research Parameters to Characterize and Differentiate Convalescent Patients from Active SARS-CoV-2 Infection. <i>Cells</i> , 2021, 10, 2332.	1.8	17
678	Computational simulations to dissect the cell immune response dynamics for severe and critical cases of SARS-CoV-2 infection. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 211, 106412.	2.6	14
680	Prevalence and characteristics of malaria among COVID-19 individuals: A systematic review, meta-analysis, and analysis of case reports. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009766.	1.3	41
681	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. <i>Kidney International</i> , 2021, 100, 915-927.	2.6	4
682	Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. <i>Clinical Immunology</i> , 2021, 231, 108804.	1.4	5
683	Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries. <i>International Immunopharmacology</i> , 2021, 99, 108050.	1.7	14
684	A novel hypothesis for COVID-19 pathogenesis: Retinol depletion and retinoid signaling disorder. <i>Cellular Signalling</i> , 2021, 87, 110121.	1.7	23
685	Immune response variables and viral mutations impact on COVID-19 reinfection and relapse. <i>International Immunopharmacology</i> , 2021, 100, 108108.	1.7	7
686	Comprehensive Laboratory Data Analysis to Predict the Clinical Severity of Coronavirus Disease 2019 in 1,952 Patients in Daegu, Korea. <i>Annals of Laboratory Medicine</i> , 2022, 42, 24-35.	1.2	12
687	Analysis of Vaccination Background in Children Undergone SARS-CoV-2 Infection. <i>Pediatric Farmakologi</i> , 2021, 17, 508-518.	0.1	1
689	COVID-19 Infection in the Human Reproductive Tract of Men and Nonpregnant Women. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	14
690	Dynamic Changes of Lymphocyte Subsets in the Course of COVID-19. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 254-262.	0.9	36
691	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. , 2021, 12, 155.		25
692	Mechanisms of infection by SARS-CoV-2, inflammation and potential links with the microbiome. <i>Future Virology</i> , 2021, 16, 43-57.	0.9	10
693	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	14
694	SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals. <i>Immune Network</i> , 2021, 21, e2.	1.6	12
695	Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. <i>Frontiers in Medicine</i> , 2020, 7, 603961.	1.2	49
696	The role of NK cells in fighting the virus infection and sepsis. <i>International Journal of Medical Sciences</i> , 2021, 18, 3236-3248.	1.1	22

#	ARTICLE	IF	CITATIONS
697	A Rare Case of Varicella-Zoster Virus Reactivation Following Recovery From COVID-19. <i>Cureus</i> , 2021, 13, e12423.	0.2	22
698	Serum albumin concentrations are associated with disease severity and outcomes in coronavirus 19 disease (COVID-19): a systematic review and meta-analysis. <i>Clinical and Experimental Medicine</i> , 2021, 21, 343-354.	1.9	50
699	Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities. <i>Theranostics</i> , 2021, 11, 8234-8253.	4.6	16
700	Chemokines and chemokine receptors during COVID-19 infection. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 976-988.	1.9	148
701	The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases. <i>Modern Rheumatology</i> , 2021, 31, 927-932.	0.9	4
702	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <i>Molecular Biomedicine</i> , 2021, 2, 1.	1.7	20
703	Secondary Infections in Critically Ill Patients with COVID-19. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2021, , 43-52.	0.1	0
705	Early Differences in Cytokine Production by Severity of Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 1145-1149.	1.9	80
706	Potential Antiviral Immune Response Against COVID-19: Lessons Learned from SARS-CoV. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 149-167.	0.8	4
708	Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	103
709	Predictive Value of Prognostic Nutritional Index on COVID-19 Severity. <i>Frontiers in Nutrition</i> , 2020, 7, 582736.	1.6	22
710	Ratios between circulating myeloid cells and lymphocytes are associated with mortality in severe COVID-19 patients. <i>Open Medicine (Poland)</i> , 2021, 16, 351-360.	0.6	0
711	Cell-mediated immunity to SARS-CoV-2. <i>Pediatric Investigation</i> , 2020, 4, 281-291.	0.6	21
712	COVID-19 Detection via Wavelet Entropy and Biogeography-Based Optimization. <i>Lecture Notes on Data Engineering and Communications Technologies</i> , 2021, , 69-76.	0.5	8
713	The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?. <i>Cell Host and Microbe</i> , 2020, 27, 863-869.	5.1	192
714	Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). <i>Pulmonology</i> , 2021, 27, 486-492.	1.0	33
715	Behavioral strategies to prevent and mitigate COVID-19 infection. <i>Sports Medicine and Health Science</i> , 2020, 2, 115-125.	0.7	3
716	Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 294.	7.1	62

#	ARTICLE	IF	CITATIONS
717	Dysregulation of type I interferon responses in COVID-19. <i>Nature Reviews Immunology</i> , 2020, 20, 397-398.	10.6	374
718	Innate immunology in COVID-19 – a living review. Part II: dysregulated inflammation drives immunopathology. <i>Oxford Open Immunology</i> , 2020, 1, iqaa005.	1.2	18
719	T cell phenotypes in COVID-19 - a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqaa007.	1.2	19
767	Herpes zoster might be an indicator for latent COVID-19 infection. <i>Dermatologic Therapy</i> , 2020, 33, e13666.	0.8	79
768	Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. <i>JCI Insight</i> , 2020, 5, .	2.3	245
769	COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes. <i>Journal of Clinical Investigation</i> , 2020, 130, 6290-6300.	3.9	168
770	Is innate immunity our best weapon for flattening the curve?. <i>Journal of Clinical Investigation</i> , 2020, 130, 3954-3956.	3.9	11
771	Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. <i>Journal of Clinical Investigation</i> , 2020, 130, 6588-6599.	3.9	128
772	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 6656-6667.	3.9	101
773	The lethal sex gap: COVID-19. <i>Immunity and Ageing</i> , 2020, 17, 13.	1.8	68
774	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. <i>F1000Research</i> , 2020, 9, 514.	0.8	12
775	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. <i>F1000Research</i> , 2020, 9, 514.	0.8	10
776	The COVID-19 pandemic: catching up with the cataclysm. <i>F1000Research</i> , 2020, 9, 638.	0.8	8
777	Effective immunity and second waves: a dynamic causal modelling study. <i>Wellcome Open Research</i> , 2020, 5, 204.	0.9	6
778	Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy. <i>World Journal of Clinical Cases</i> , 2020, 8, 5835-5843.	0.3	11
779	SARS-CoV-2 infection induces mixed M1/M2 phenotype in circulating monocytes and alterations in both dendritic cell and monocyte subsets. <i>PLoS ONE</i> , 2020, 15, e0241097.	1.1	27
780	Early predictive factors of progression from severe type to critical ill type in patients with Coronavirus Disease 2019: A retrospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0243195.	1.1	4
781	Pre-test probability for SARS-Cov-2-related infection score: The PARIS score. <i>PLoS ONE</i> , 2020, 15, e0243342.	1.1	24



#	ARTICLE	IF	CITATIONS
782	Clinical outcomes and inflammatory marker levels in patients with Covid-19 and obesity at an inner-city safety net hospital. PLoS ONE, 2020, 15, e0243888.	1.1	16
783	Clinical features and risk factors for severe inpatients with COVID-19: A retrospective study in China. PLoS ONE, 2020, 15, e0244125.	1.1	12
784	The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors. PLoS Pathogens, 2020, 16, e1009013.	2.1	77
785	IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 245-261.	0.2	16
786	Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer. Clinical Chemistry and Laboratory Medicine, 2021, 59, 783-793.	1.4	26
787	Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes. EMBO Molecular Medicine, 2020, 12, e13038.	3.3	48
788	Coronaviral Infection (COVID-19) in Children (Situation on April 2020). PediatriĀeskaĀ FarmakologiĀ, 2020, 17, 85-94.	0.1	14
789	COVID-19: etiology, clinical picture, treatment. Russian Journal of Infection and Immunity, 2020, 10, 421-445.	0.2	36
790	Lung Pathology of COVID-19 in Moscow. Arkhiv Patologii, 2020, 82, 32.	0.0	23
791	The Effects of COVID 19 on Health Care Workers: Analysing of the Interaction between Optimism, Job Stress and Emotional Exhaustion. International and Multidisciplinary Journal of Social Sciences, 0, , .	0.5	17
792	COVID-19 and children. Pulmonologiya, 2020, 30, 609-628.	0.2	15
793	Effect of COVID-19 Infection on the Immune System and Risk of Developing Diabetes Complications: A Review. Journal of Pharmaceutical Care, 0, , .	0.0	1
794	Reversing immunosenescence for prevention of COVID-19. Aging, 2020, 12, 11161-11162.	1.4	7
795	Sex differences in clinical characteristics and risk factors for mortality among severe patients with COVID-19: a retrospective study. Aging, 2020, 12, 18833-18843.	1.4	20
796	Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19. Aging, 2020, 12, 26263-26278.	1.4	25
797	PATHOLOGICAL ANATOMY OF INFECTION CAUSED BY SARS-COV-2. Russian Journal of Forensic Medicine, 2020, 6, 8-30.	0.0	37
798	Pandemic of Infectious Diseases due to New Etiological Agents Predisposing Factors, Case study of COVID19 and Control Measures. International Journal of Current Microbiology and Applied Sciences, 2020, 9, 3424-3457.	0.0	1
800	Can wearing face masks in public affect transmission route and viral load in COVID-19?. Central European Journal of Public Health, 2020, 28, 161-162.	0.4	16

#	ARTICLE	IF	CITATIONS
801	Development and External Validation of a Prognostic Multivariable Model on Admission for Hospitalized Patients with COVID-19. SSRN Electronic Journal, 0, , .	0.4	36
802	Synergic Viral-Bacterial Co-Infection in Catalase-Deficient COVID-19 Patients Causes Suppressed Innate Immunity and Lung Damages Due to Detrimental Elevation of Hydrogen Peroxide Concentration. SSRN Electronic Journal, 0, , .	0.4	5
803	Plasmapheresis with corticosteroids and antiviral: a life-saving treatment for severe cases of Covid 19. Caspian Journal of Internal Medicine, 2020, 11, 572-576.	0.1	4
804	Parallels in the pathogenesis of SARS-CoV-2 and <i>M. tuberculosis</i>: a synergistic or antagonistic alliance?. Future Microbiology, 2020, 15, 1691-1695.	1.0	15
805	Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma. Acta Biomedica, 2020, 91, ahead of print.	0.2	27
806	The Role of Nutrients in Supporting The Immune System Against Viral Infection; Newly Emerged Coronavirus (COVID-19): A Narrative Review. Kurdistan Journal of Applied Research, 0, , 84-96.	0.4	3
807	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Science Alliance, 2021, 4, e202000955.	1.3	56
808	Neutrophils, NETs, NETosis and their paradoxical roles in COVID-19. Journal of Stem Cell Therapy and Transplantation, 2020, 4, 003-010.	0.2	5
809	Seasonal variations in Nigeria: understanding COVID-19 transmission dynamics and immune responses. Journal of Global Health Reports, 0, 4, .	1.0	4
810	A Narrative Review of COVID-19: The New Pandemic Disease. Iranian Journal of Medical Sciences, 2020, 45, 233-249.	0.3	30
811	COVID-19 and the Immune System. Physiological Research, 2020, 69, 379-388.	0.4	245
812	The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19. Cells, 2021, 10, 30.	1.8	30
813	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses, 2021, 13, 26.	1.5	26
814	Neurological complications of SARS-CoV-2 coronavirus infection (COVID-19). Neurologie Pro Praxi, 2020, 21, 14-14.	0.0	1
815	Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review). International Journal of Oncology, 2020, 58, 145-157.	1.4	55
816	Re-emergence of TIVA in COVID times. Indian Journal of Anaesthesia, 2020, 64, 125.	0.3	13
817	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. Indian Journal of Ophthalmology, 2020, 68, 693.	0.5	78
818	Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19. Immune Network, 2020, 20, e28.	1.6	8

#	ARTICLE	IF	CITATIONS
819	Complex mechanism of COVID-19 development. SeĀenovskij Vestnik, 2020, 11, 50-61.	0.3	13
820	Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 353-367.	0.2	33
821	Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab). Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 456-462.	0.2	7
822	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. Allergologie Select, 2020, 4, 44-52.	1.6	23
823	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. PeerJ, 2020, 8, e10322.	0.9	47
824	Herpes Zoster Co-Infection in an Immunocompetent Patient With COVID-19. Cureus, 2020, 12, e8998.	0.2	29
825	COVID-19 as a Possible Cause of Functional Exhaustion of CD4 and CD8 T-cells and Persistent Cause of Methicillin-Sensitive Staphylococcus aureus Bacteremia. Cureus, 2020, 12, e9000.	0.2	13
826	Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients. Journal of Infectious Diseases, 2021, 224, 1849-1860.	1.9	16
827	Systems and Longitudinal Analysis Reveals Early-Stage and Highly Coordinated Immune Responses in Mild COVID-19 Patients. SSRN Electronic Journal, 0, , .	0.4	0
828	Inflammation from the Standpoint of Leukocytes. , 2021, , 19-43.		0
829	Is malaria immunity a possible protection against severe symptoms and outcomes of COVID-19?. Ghana Medical Journal, 2021, 55, 56-63.	0.1	7
830	Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS-CoV-2 RNA. Journal of Molecular Cell Biology, 2021, 13, 748-759.	1.5	10
831	A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. Trials, 2021, 22, 674.	0.7	8
832	COVID and Lung Cancer. Current Oncology Reports, 2021, 23, 134.	1.8	21
833	Presence and clinical impact of human herpesvirusĀ6 infection in patients with moderate to critical coronavirus diseaseĀ19. Journal of Medical Virology, 2022, 94, 1212-1216.	2.5	11
834	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. Seminars in Immunology, 2021, 55, 101508.	2.7	37
835	Untimely TGFĀ2 responses in COVID-19 limit antiviral functions of NK cells. Nature, 2021, 600, 295-301.	13.7	146
836	Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nature Communications, 2021, 12, 5839.	5.8	67

#	ARTICLE	IF	CITATIONS
837	Adipose-Tissue-Derived Mesenchymal Stem Cells Mediate PD-L1 Overexpression in the White Adipose Tissue of Obese Individuals, Resulting in T Cell Dysfunction. <i>Cells</i> , 2021, 10, 2645.	1.8	18
838	The link between <i>Toxoplasma gondii</i> infections and higher mortality in COVID-19 patients having schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 167-168.	1.8	9
839	Complete blood count alterations in COVID-19 patients. <i>Biochemia Medica</i> , 2021, 31, 403-415.	1.2	63
840	Post-COVID fungal infections of maxillofacial region: a systematic review. <i>Oral and Maxillofacial Surgery</i> , 2022, 26, 357-363.	0.6	9
841	Uncertainty around the Long-Term Implications of COVID-19. <i>Pathogens</i> , 2021, 10, 1267.	1.2	16
842	Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 658932.	1.6	5
843	An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19. <i>International Immunopharmacology</i> , 2021, 101, 108226.	1.7	1
844	Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112230.	2.5	33
845	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
846	The Chemical Sciences' Advances on Coronavirus Disease 2019 (COVID-19). <i>Asian Journal of Organic &amp; Medicinal Chemistry</i> , 2020, 5, 179-184.	0.1	0
847	Herpes zoster coinfection and the current COVID-19 pandemic. <i>Saudi Critical Care Journal</i> , 2020, 4, 130.	0.4	1
849	Human immune response to SARS-CoV-2: What is known? A scoping review. <i>Infectio</i> , 2020, 24, 26.	0.4	1
852	COVID-19: an updated review. <i>Russian Journal of Infection and Immunity</i> , 2020, 10, 247-258.	0.2	2
853	La respuesta inmune frente a SARS-CoV-2, ¿un arma de doble filo?. <i>Revista De Investigaci3n Y Educaci3n En Ciencias De La Salud (RIECS)</i> , 2020, 5, 134-142.	0.0	0
854	Imunidade na Infe3o pelo SARS-CoV-2: O que Sabemos. <i>Revista De Medicina Internaf, Neurologie, Psiquiatrie, Neurocirurgie, Dermato-venerologie Medicina Internaf</i> , 2020, 27, .	0.0	0
856	Fundamental Basis of COVID-19 Pathogenesis. <i>Serbian Journal of Experimental and Clinical Research</i> , 2020, 21, 93-111.	0.2	3
857	Emerging details about COVID-19 and chronology of the pandemic in Turkey. <i>Ankara Universitesi Veteriner Fakultesi Dergisi</i> , 2020, 67, 323-332.	0.4	6
859	Coronaviral Infection (COVID-19) in Children (Situation on June 2020). <i>PediatriĖskaĖ FarmakologiĖ</i> , 2020, 17, 162-178.	0.1	6

#	ARTICLE	IF	CITATIONS
862	An Unusual Case of Moraxella osloensis Bacteremia in an Immunocompetent Patient With SARS-CoV-2 Infection. <i>Cureus</i> , 2020, 12, e10154.	0.2	1
864	Potential Treatment of COVID-19 with Traditional Chinese Medicine: What Herbs Can Help Win the Battle with SARS-CoV-2?. <i>Engineering</i> , 2022, 19, 139-152.	3.2	20
865	Gamma Delta T Cells and Their Involvement in COVID-19 Virus Infections. <i>Frontiers in Immunology</i> , 2021, 12, 741218.	2.2	21
866	Differential dynamics of peripheral immune responses to acute SARS-CoV-2 infection in older adults. <i>Nature Aging</i> , 2021, 1, 1038-1052.	5.3	10
868	COVID-19 pathology: experience of 2000 autopsies. <i>Russian Journal of Forensic Medicine</i> , 2020, 6, 10-23.	0.0	8
869	Three Probable Pediatrics COVID-19 Cases with Kawasaki-like Disease: A Case Series with Follow-up. <i>Archives of Pediatric Infectious Diseases</i> , 2020, 9, .	0.1	0
870	nCOVID-19: Its diagnosis, possible preventive measures, therapeutic interventions and management. <i>Archives of Community Medicine and Public Health</i> , 2020, , 115-129.	0.1	0
871	The importance of physical activity in management of type 2 diabetes and COVID-19. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110546.	1.4	16
872	Exploring the Mediation Effect of Awareness and Quarantine in Affecting Rate: A Study on COVID-19. <i>SSRN Electronic Journal</i> , 2020, , 3624017.	0.4	0
873	Transcriptomic Signatures and Immunomodulatory Treatments for COVID-19 Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
874	Impaired T Cell Functions Along with Elevated Activated Tregs at the Early Stage of Asymptomatic SARS-CoV-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
876	SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity. <i>Cellular Immunology</i> , 2022, 371, 104454.	1.4	18
877	COVID-19 in pregnant women and children: Insights on clinical manifestations, complexities, and pathogenesis. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 156, 216-224.	1.0	14
878	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
879	T Cell Immunity Evaluation and Immunodominant Epitope T Cell Receptor Identification of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein in COVID-19 Convalescent Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 696662.	1.8	5
880	Diabetes mellitus and COVID-19: review of a lethal interaction from the cellular and molecular level to the bedside. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 1-19.	1.2	2
881	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?. <i>Frontiers in Immunology</i> , 2021, 12, 797117.	2.2	4
882	Características y especialización de la respuesta inmunitaria en la COVID-19. <i>Revista De La Facultad De Medicina, Universidad Nacional Autonoma De Mexico</i> , 2020, 63, 7-18.	0.0	6

#	ARTICLE	IF	CITATIONS
889	Effective immunity and second waves: a dynamic causal modelling study. Wellcome Open Research, 2020, 5, 204.	0.9	7
893	Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery. Integrative Medicine, 2020, 19, 8-35.	0.1	8
894	Magnesium and Vitamin D Deficiency as a Potential Cause of Immune Dysfunction, Cytokine Storm and Disseminated Intravascular Coagulation in covid-19 patients. Missouri Medicine, 2021, 118, 68-73.	0.3	11
895	Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling. Tanaffos, 2020, 19, 274-290.	0.5	5
896	Decreased Serum Levels of Angiotensin Converting Enzyme (ACE)2 and Enhanced Cytokine Levels with Severity of COVID-19: Normalisation Upon Disease Recovery. SSRN Electronic Journal, 0, , .	0.4	0
897	Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes. Theranostics, 2022, 12, 290-306.	4.6	11
898	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses " are we our own worst enemy?. Nature Reviews Immunology, 2022, 22, 47-56.	10.6	118
899	PD-1 blockade counteracts post"COVID-19 immune abnormalities and stimulates the anti" SARS-CoV-2 immune response. JCI Insight, 2021, 6, .	2.3	51
900	Jinhua Qinggan granule, a Chinese herbal medicine against COVID"19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL"6 and IFN"3: An open" label, single" arm pilot study. World Academy of Sciences Journal, 2021, 4, .	0.4	7
901	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurology, 2021, 21, 462.	0.8	4
902	SARS-CoV-2: Overview and Its Impact on Oral Health. Biomedicines, 2021, 9, 1690.	1.4	7
903	Global Pandemic as a Result of Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak: A Biomedical Perspective. Journal of Pure and Applied Microbiology, 0, , .	0.3	0
904	Activation of Intracellular Complement in Lungs of Patients With Severe COVID-19 Disease Decreases T-Cell Activity in the Lungs. Frontiers in Immunology, 2021, 12, 700705.	2.2	6
905	Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course. Viruses, 2021, 13, 2246.	1.5	6
906	Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities. Frontiers in Immunology, 2021, 12, 778913.	2.2	5
907	Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. Current HIV/AIDS Reports, 2022, 19, 5-16.	1.1	9
908	How Immunosenescence and Inflammaging May Contribute to Hyperinflammatory Syndrome in COVID-19. International Journal of Molecular Sciences, 2021, 22, 12539.	1.8	24
909	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	2.7	72

#	ARTICLE	IF	CITATIONS
910	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Pathogens</i> , 2021, 10, 1537.	1.2	19
912	Immunological and Preventive Effects of Hochuekkito and Kakkonto Against Coronavirus Disease in Healthcare Workers: A Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 766402.	1.6	3
913	COVID19 Pandemic and Children. , 2022, , 811-830.		0
914	Pathogenesis of Respiratory Viral and Fungal Coinfections. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0009421.	5.7	64
915	Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. <i>Translational Research</i> , 2022, 241, 1-12.	2.2	15
916	The role of polyspecific T-cell exhaustion in severe outcomes for COVID-19 patients having latent pathogen infections such as <i>Toxoplasma gondii</i> . <i>Microbial Pathogenesis</i> , 2021, 161, 105299.	1.3	2
917	Identifying SARS-CoV-2 memory <sup>+</sup> NK cells from COVID-19 convalescent donors for adoptive cell therapy. <i>Immunology</i> , 2022, 165, 234-249.	2.0	18
919	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4714-4740.	1.4	16
920	Herpes Zoster Following Covaxin Receipt. <i>International Medical Case Reports Journal</i> , 2021, Volume 14, 819-821.	0.3	6
921	Role of Artificial Intelligence in COVID-19 Detection. <i>Sensors</i> , 2021, 21, 8045.	2.1	32
922	The immunology and immunotherapy for COVID-19. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e24.	1.6	2
923	The adaptation of SARS-CoV-2 to humans. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 116, e210127.	0.8	4
924	Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 63-72.	0.5	2
925	Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, e0150421.	1.2	17
926	Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. <i>Life Science Alliance</i> , 2022, 5, e202101200.	1.3	26
927	Coronavirus Disease 2019 (COVID-19): Pathogenesis, Immune Responses, and Treatment Options. <i>Asian Journal of Research in Infectious Diseases</i> , 0, , .	0.0	0
928	Management of Chronic Myeloid Leukemia with Sever COVID 19: A Case Report. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 304-308.	0.1	2
929	Pulmonary pathology of COVID-19. <i>Journal of Lung, Pulmonary &amp; Respiratory Research</i> , 2020, 7, 79-83.	0.3	0

#	ARTICLE	IF	CITATIONS
930	NK cells at the crossroads in COVID-19: a question of timing. <i>Ciencia, Tecnología y Salud</i> , 2020, 7, 309-324.	0.0	1
931	ĐžĐ;ĐžĐ'Đ~Đ'ĐžĐ;ĐĐĐ† Đ†ĐœĐŁĐĐ†ĐĐĐ•ĐĐĐŁ ĐŸĐĐ~ COVID-19. <i>Immunology and Allergy Science and Practice</i> 2020, ,65-15.		
932	Cardiovascular Burden of COVID-19 and the Post-Covid Era. , 2021, 1, 1-10.		0
933	COVID-19 Tedavisinde Mezenkimal KÃ¼k HÃ¼crelerin Potansiyel KullanÄ±mÄ± Äœezerine KapsamlÄ± Bir Ä°nceleme. , 2021, 4, 31-65.		0
934	Single-cell immunology of SARS-CoV-2 infection. <i>Nature Biotechnology</i> , 2022, 40, 30-41.	9.4	78
935	An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution. <i>Biomedicines</i> , 2022, 10, 296.	1.4	25
936	Impact of COVIDâ€19 in hematopoietic stem cell transplant recipients: A systematic review and metaâ€analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	28
937	Potential metal-related strategies for prevention and treatment of COVID-19. <i>Rare Metals</i> , 2022, 41, 1-13.	3.6	5
938	Vitamin D can reduce severity in COVID-19 through regulation of PD-L1. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 487-494.	1.4	9
939	Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 793142.	2.2	13
940	Innate immunological pathways in COVID-19 pathogenesis. <i>Science Immunology</i> , 2022, 7, eabm5505.	5.6	101
941	Can Nutritional Supports Beneficial in Other Viral Diseases Be Favorable for COVID-19?. <i>Korean Journal of Family Medicine</i> , 2022, 43, 3-15.	0.4	1
942	Monoclonal Antibodies and their Target Specificity Against SARS-CoV-2 Infections: Perspectives and Challenges. <i>Recent Patents on Biotechnology</i> , 2022, 16, 64-78.	0.4	3
943	Exosomes and COVID-19: challenges and opportunities. <i>Comparative Clinical Pathology</i> , 2022, 31, 347-354.	0.3	12
944	Long non-coding RNAs (lncRNAs) NEAT1 and MALAT1 are differentially expressed in severe COVID-19 patients: An integrated single-cell analysis. <i>PLoS ONE</i> , 2022, 17, e0261242.	1.1	37
945	The transcription factor Eomes promotes expression of inhibitory receptors on hepatic CD8<sup>+</sup> T cells during HBV persistence. <i>FEBS Journal</i> , 2022, 289, 3241-3261.	2.2	6
946	COVID-19: systemic pathology and its implications for therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 386-408.	2.6	27
947	COVIDâ€19 immunopathology with emphasis on Th17 response and cellâ€based immunomodulation therapy: Potential targets and challenges. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13131.	1.3	19



#	ARTICLE	IF	CITATIONS
948	Cancer and COVID-19 Susceptibility and Severity: A Two-Sample Mendelian Randomization and Bioinformatic Analysis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 759257.	1.8	6
949	Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination. <i>Vaccines</i> , 2022, 10, 114.	2.1	3
950	Discovering potential interactions between rare diseases and COVID-19 by combining mechanistic models of viral infection with statistical modeling. <i>Human Molecular Genetics</i> , 2022, , .	1.4	1
951	Is the epithelial barrier hypothesis the key to understanding the higher incidence and excess mortality during COVID-19 pandemic? The case of Northern Italy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1408-1417.	2.7	13
952	NK cell dysfunction in patients with COVID-19. <i>Cellular and Molecular Immunology</i> , 2022, 19, 127-129.	4.8	35
953	The COVID-19 infection in children and its association with the immune system, prenatal stress, and neurological complications. <i>International Journal of Biological Sciences</i> , 2022, 18, 707-716.	2.6	15
954	Bioinformatic Analysis Identifies Biomarkers and Treatment Targets in Primary Sjögren's Syndrome Patients with Fatigue. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	2
955	Prognostic factors for predicting severity and mortality in hospitalized COVID-19 patients. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24216.	0.9	7
956	Cancer Occurrence as the Upcoming Complications of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 813175.	1.6	12
957	Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 801410.	2.2	6
958	Severe acute respiratory syndrome coronavirus 2, primary varicella zoster virus coinfection, and a polymicrobial ventilator-associated tracheobronchitis in an adult immunocompetent male: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, 45.	0.4	1
960	Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides. <i>Journal of Human Genetics</i> , 2022, 67, 411-419.	1.1	5
961	Systems analysis of immune responses to attenuated <i>P. falciparum</i> malaria sporozoite vaccination reveals excessive inflammatory signatures correlating with impaired immunity. <i>PLoS Pathogens</i> , 2022, 18, e1010282.	2.1	9
963	New Discovery of Myeloid-Derived Suppressor Cell's Tale on Viral Infection and COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 842535.	2.2	7
964	Pathological effects of SARS-CoV-2 on hematological and immunological cells: Alterations in count, morphology, and function. <i>Pathology Research and Practice</i> , 2022, 231, 153782.	1.0	16
965	The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection. <i>Prostaglandins and Other Lipid Mediators</i> , 2022, 159, 106619.	1.0	16
966	Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. <i>International Immunopharmacology</i> , 2022, 105, 108531.	1.7	1
967	Pregnant Women Develop a Specific Immunological Long-Lived Memory Against SARS-COV-2. <i>Frontiers in Immunology</i> , 2022, 13, 827889.	2.2	5

#	ARTICLE	IF	CITATIONS
968	Inflammatory Markers, Pulmonary Function, and Clinical Symptoms in Acute COVID-19 Among Non-Hospitalized Adolescents and Young Adults. <i>Frontiers in Immunology</i> , 2022, 13, 837288.	2.2	15
969	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. <i>Medicina (Lithuania)</i> , 2022, 58, 261.	0.8	3
970	Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking. Network Modeling Analysis in Health Informatics and Bioinformatics, 2022, 11, 11.	1.2	5
971	Cardiovascular risk among people of all ages during the recovery period after COVID-19 (1-3 months) in the background of morbid obesity of the first stage. <i>Ageing &amp; Longevity</i> , 2021, , 40-49.	0.1	0
972	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals"EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12
973	Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report. <i>IDCases</i> , 2022, 27, e01452.	0.4	3
974	In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production. <i>Life</i> , 2022, 12, 244.	1.1	6
975	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
976	Reactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically Ill COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers. <i>Microorganisms</i> , 2022, 10, 362.	1.6	14
977	Investigations on the Control of COVID-19 and Suggestions for Re-Open Based on Model Study. <i>Mathematics</i> , 2022, 10, 22.	1.1	0
979	The pigtail macaque ( <i>Macaca nemestrina</i> ) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease. <i>PLoS Pathogens</i> , 2021, 17, e1010162.	2.1	11
980	Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 788769.	2.2	18
981	Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents. <i>Frontiers in Immunology</i> , 2021, 12, 797919.	2.2	13
982	SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 168-190.	0.0	0
983	Stromal and endothelial herpes simplex virus keratitis reactivation in the convalescent period of COVID-19 "A case report. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 1410.	0.5	2
984	Chronic diseases, chest computed tomography, and laboratory tests as predictors of severe respiratory failure and death in elderly Brazilian patients hospitalized with COVID-19: a prospective cohort study. <i>BMC Geriatrics</i> , 2022, 22, 132.	1.1	1
985	Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. <i>Journal of Personalized Medicine</i> , 2022, 12, 349.	1.1	3
986	New Approach for Targeted Treatment of Mild COVID-19 by Honeysuckle through Network Pharmacology Analysis. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-12.	0.7	1

#	ARTICLE	IF	CITATIONS
987	Post-COVID-19 HSV encephalitis: a review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 222-227.	0.2	11
988	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 57.	7.1	34
989	T cell responses to SARS-CoV-2 in humans and animals. <i>Journal of Microbiology</i> , 2022, 60, 276-289.	1.3	8
990	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 142.	2.4	24
991	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. <i>Immunologic Research</i> , 2022, 70, 289-315.	1.3	34
992	Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery. <i>Heliyon</i> , 2022, 8, e08957.	1.4	3
993	Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 675-684.	2.0	24
994	Innate Immune Response in SARS-CoV-2 Infection. <i>Microorganisms</i> , 2022, 10, 501.	1.6	13
995	Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19. <i>Frontiers in Genetics</i> , 2022, 13, 845474.	1.1	15
996	Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19. <i>Molecular Biology Reports</i> , 2022, 49, 5153-5163.	1.0	4
997	Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdrop: A Novel Perspective. <i>International Journal of Diabetology</i> , 2022, 3, 193-235.	0.9	6
998	Programmed cell death: the pathways to severe COVID-19?. <i>Biochemical Journal</i> , 2022, 479, 609-628.	1.7	30
999	SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells. <i>Cell Reports</i> , 2022, 38, 110503.	2.9	31
1000	Understanding the role of vitamin A and its precursors in the immune system. <i>Nutrition Clinique Et Metabolisme</i> , 2022, 36, 89-98.	0.2	7
1001	COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response. <i>Acta Haematologica</i> , 2022, 145, 297-309.	0.7	7
1002	Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3636.	1.8	190
1003	Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review. <i>Frontiers in Immunology</i> , 2022, 13, 835104.	2.2	28
1004	TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19. <i>Viruses</i> , 2022, 14, 739.	1.5	19

#	ARTICLE	IF	CITATIONS
1005	Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection. <i>ELife</i> , 2022, 11, .	2.8	37
1006	Activated CD8+CD38+ Cells Are Associated With Worse Clinical Outcome in Hospitalized COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 861666.	2.2	8
1007	COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity. <i>Immunogenetics</i> , 2022, 74, 381-407.	1.2	5
1008	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
1009	Metabolic Landscape of Bronchoalveolar Lavage Fluid in Coronavirus Disease 2019 at Single Cell Resolution. <i>Frontiers in Immunology</i> , 2022, 13, 829760.	2.2	1
1010	Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. <i>OncImmunology</i> , 2022, 11, 2046931.	2.1	19
1011	Transcriptome Analysis of Lungs in a Mouse Model of Severe COVID-19. <i>Frontiers in Virology</i> , 2022, 2, .	0.7	3
1012	Definition of the Immune Parameters Related to COVID-19 Severity. <i>Frontiers in Immunology</i> , 2022, 13, 850846.	2.2	4
1013	The number of circulating <sc>CD26</sc> expressing cells is decreased in critical <sc>COVID</sc>-19 illness. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 153-161.	1.1	2
1014	Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 870283.	2.2	14
1015	The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity. <i>Virology Journal</i> , 2022, 19, 49.	1.4	34
1016	Metabolic programs tailor T cell immunity in viral infection, cancer, and aging. <i>Cell Metabolism</i> , 2022, 34, 378-395.	7.2	41
1017	Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. <i>Stem Cell Research and Therapy</i> , 2022, 13, 122.	2.4	29
1018	Dysfunctional State of T Cells or Exhaustion During Chronic Viral Infections and COVID-19: A Review. <i>Viral Immunology</i> , 2022, 35, 284-290.	0.6	5
1019	Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients. <i>Cell Reports Medicine</i> , 2022, 3, 100600.	3.3	10
1020	COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery. <i>Biomedicines</i> , 2022, 10, 776.	1.4	8
1021	Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. <i>Journal of Infection and Public Health</i> , 2022, 15, 466-479.	1.9	21
1022	CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. <i>Frontiers in Immunology</i> , 2022, 13, 864298.	2.2	11

#	ARTICLE	IF	CITATIONS
1023	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. <i>Clinical and Experimental Medicine</i> , 2023, 23, 313-331.	1.9	21
1024	The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections. <i>Frontiers in Immunology</i> , 2022, 13, 832394.	2.2	56
1025	Association of vitamin D status with COVID-19 disease severity in pediatric patients: A retrospective observational study. <i>Health Science Reports</i> , 2022, 5, e569.	0.6	6
1026	Stratification of COVID-19 patients based on quantitative immune-related gene expression in whole blood. <i>Molecular Immunology</i> , 2022, 145, 17-26.	1.0	4
1027	Immunosenescence and COVID-19. <i>Mechanisms of Ageing and Development</i> , 2022, 204, 111672.	2.2	35
1028	COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches. <i>International Immunopharmacology</i> , 2022, 107, 108655.	1.7	8
1029	Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 52-73.	1.8	11
1030	SARS-CoV-2 induces mitochondrial dysfunction and cell death by oxidative stress/inflammation in leukocytes of COVID-19 patients. <i>Free Radical Research</i> , 2021, 55, 982-995.	1.5	13
1031	The immunologic response to severe acute respiratory syndrome coronavirus 2. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 495-505.	1.0	5
1032	Implications of Vitamins in COVID-19 Prevention and Treatment through Immunomodulatory and Anti-Oxidative Mechanisms. <i>Antioxidants</i> , 2022, 11, 5.	2.2	9
1033	Microbiota and intestinal permeability as drivers of gastroenterological manifestations of new coronavirus infection (COVID-19). <i>Jurnal Infektologii</i> , 2021, 13, 57-65.	0.1	2
1034	Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic. <i>Tumori</i> , 2021, , 030089162110639.	0.6	4
1035	Potential of germanium-based compounds in coronavirus infection. <i>Acta Pharmaceutica</i> , 2022, 72, 245-258.	0.9	5
1036	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
1037	Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 789317.	2.2	34
1038	Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis. <i>Medical Journal of Indonesia</i> , 2022, 30, 264-78.	0.2	1
1040	Modeling Early Phases of COVID-19 Pandemic in Northern Italy and Its Implication for Outbreak Diffusion. <i>Frontiers in Public Health</i> , 2021, 9, 724362.	1.3	2
1041	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 5815.	1.0	6

#	ARTICLE	IF	CITATIONS
1042	Inhibitory Immune Checkpoint Molecules and Exhaustion of T cells in COVID-19. <i>Physiological Research</i> , 2021, 70, S227-S247.	0.4	13
1043	Interferon Gamma Release Assay Mitogen Responses in COVID-19. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, .	0.1	3
1044	The systemic immunosuppressive effects of peripheral corticosteroid injections: A narrative review of the evidence in the context of COVID-19. <i>Musculoskeletal Care</i> , 2022, 20, 431-441.	0.6	6
1045	Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 763460.	2.2	16
1046	Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses. <i>Microorganisms</i> , 2021, 9, 2578.	1.6	1
1047	Role of the cellular immunity in the formation of the immune response in coronavirus infections. <i>Medical Immunology (Russia)</i> , 2021, 23, 1229-1238.	0.1	3
1048	A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune-epithelial interface. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
1049	Immune Response to COVID-19. , 0, , .		1
1050	ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report. <i>American Journal of Transplantation</i> , 2022, 22, 1261-1265.	2.6	24
1051	Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12173.	5.5	19
1052	COVID-19 and ophthalmic herpes zoster co-infection in immunocompetent patient. <i>Bali Dermatology and Venereology Journal</i> , 2021, 4, .	0.1	0
1053	A fatal rhino-orbit-cerebral mucormycosis infection aggravated by coronavirus disease-2019. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2022, 55, e06662021.	0.4	0
1054	Risk factors of the severe course and fatal outcome in COVID-19. <i>Physical and Rehabilitation Medicine Medical Rehabilitation</i> , 2022, 4, 14-36.	0.1	11
1055	SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 0, , .	0.3	4
1056	Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112965.	2.5	20
1057	The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients. <i>Biomedicines</i> , 2022, 10, 934.	1.4	4
1058	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. <i>International Immunopharmacology</i> , 2022, 109, 108786.	1.7	7
1059	Herpes zoster in the era of COVID-19: A prospective observational study to probe the association of herpes zoster with COVID-19 infection and vaccination. <i>Dermatologic Therapy</i> , 2022, 35, e15521.	0.8	10

#	ARTICLE	IF	CITATIONS
1060	COVID-19 Autopsies Reveal Underreporting of SARS-CoV-2 Infection and Scarcity of Co-infections. <i>Frontiers in Medicine</i> , 2022, 9, 868954.	1.2	14
1061	Assessment of changes in immune status linked to COVID-19 convalescent and its clinical severity in patients and uninfected exposed relatives. <i>Immunobiology</i> , 2022, 227, 152216.	0.8	2
1090	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. <i>Inflammation</i> , 2022, 45, 1430-1449.	1.7	16
1091	SARS-CoV-2-specific CD4+ T cells are associated with long-term persistence of neutralizing antibodies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 132.	7.1	16
1092	Allelic imbalance of HLA-B expression in human lung cells infected with coronavirus and other respiratory viruses. <i>European Journal of Human Genetics</i> , 2022, , .	1.4	10
1093	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0
1094	Spectrum of herpetic eye disease during COVID-19 pandemic. <i>Kerala Journal of Ophthalmology</i> , 2022, 34, 47.	0.1	0
1095	Dynamic response landscape of immune cells identified immune dysfunction which predicts disease progression in COVID-19 infected patients. <i>International Journal of Biological Sciences</i> , 2022, 18, 3066-3081.	2.6	1
1096	Biomarker based biosensors: An opportunity for diagnosis of COVID-19. <i>Reviews in Medical Virology</i> , 2022, 32, e2356.	3.9	6
1097	T helper cell subsets and related target cells in acute COVID-19. <i>Russian Journal of Infection and Immunity</i> , 2022, 12, 409-426.	0.2	4
1098	Microfluidics-Based Point-of-Care Testing (POCT) Devices in Dealing with Waves of COVID-19 Pandemic: The Emerging Solution. <i>ACS Applied Bio Materials</i> , 2022, 5, 2046-2068.	2.3	37
1099	Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients. <i>Heliyon</i> , 2022, 8, e09302.	1.4	7
1100	Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients â€” the BISHOP study. <i>Infectious Diseases</i> , 2022, 54, 591-599.	1.4	17
1101	Exploring the Utility of NK Cells in COVID-19. <i>Biomedicines</i> , 2022, 10, 1002.	1.4	12
1102	The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy. <i>Journal of Biomedical Science</i> , 2022, 29, 27.	2.6	9
1103	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. <i>Nature Communications</i> , 2022, 13, 2576.	5.8	21
1104	Correlation of the Imbalance in the Circulating Lymphocyte Subsets With C-Reactive Protein and Cardio-Metabolic Conditions in Patients With COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
1105	COVID-19 Re-Enfekte Hastada Periorbital Herpes Zoster Duplex Bilateralis BirlikteliÄŸi. <i>Medical Journal of Western Black Sea</i> , 2021, 5, 501-504.	0.2	0

#	ARTICLE	IF	CITATIONS
1106	The effect of Epstein-Barr virus viremia on the progression to severe COVID-19. <i>Medicine (United States)</i> , 2022, 101, 1000000.	9.4	9
1107	The association of decreased HLA-G+ immune cell frequencies with critical COVID-19 patients. <i>Microbial Pathogenesis</i> , 2022, 167, 105550.	1.3	4
1108	Reactivación del virus varicela zoster tras vacunación contra la covid 19. <i>Piel</i> , 2022, , .	0.0	0
1109	Endothelialitis, Microischemia, and Intussusceptive Angiogenesis in COVID-19. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, , a041157.	2.9	7
1110	Epidemiological and clinical characteristics of patients hospitalised with COVID-19 in Kenya: a multicentre cohort study. <i>BMJ Open</i> , 2022, 12, e049949.	0.8	8
1111	COVID-19 感染后免疫反应与 SARS-CoV-2 再激活的关系. <i>中华医学杂志</i> , 2022, 93, 1000000.	0.0	0
1112	Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview. <i>Viruses</i> , 2022, 14, 1082.	1.5	20
1113	SARS-CoV-2 Infection Dysregulates Host Iron (Fe)-Redox Homeostasis (Fe-R-H): Role of Fe-Redox Regulators, Ferroptosis Inhibitors, Anticoagulants, and Iron-Chelators in COVID-19 Control. <i>Journal of Dietary Supplements</i> , 2023, 20, 312-371.	1.4	12
1114	COVID-19 感染后免疫反应与 SARS-CoV-2 再激活的关系. <i>中华医学杂志</i> , 2022, 93, 1000000.	0.0	0
1116	Reactivation of Herpes Zoster Virus After COVID-19 Vaccination: Is There Any Association?. <i>Cureus</i> , 2022, , .	0.2	7
1118	A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19). <i>Cell Communication and Signaling</i> , 2022, 20, .	2.7	23
1119	Automatic Detection of Severely and Mildly Infected COVID-19 Patients with Supervised Machine Learning Models. <i>Irbm</i> , 2023, 44, 100725.	3.7	24
1120	SARS-CoV-2 and HIV co-infection; clinical features, diagnosis, and treatment strategies: A systematic review and meta-analysis. <i>Gene Reports</i> , 2022, 27, 101624.	0.4	2
1121	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1122	Characteristics of Natural Killer (NK) Cell and T Lymphocyte in COVID-19 patients in Surabaya, Indonesia. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 2198-2203.	0.2	4
1123	Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	19
1124	Dysbiosis of Gut Microbiota and Intestinal Barrier Dysfunction in Pigs with Pulmonary Inflammation Induced by <i>Mycoplasma hyorhinis</i> Infection. <i>MSystems</i> , 2022, 7, .	1.7	8
1125	Pathogenesis of SARS-CoV-2 and <i>Mycobacterium tuberculosis</i> Coinfection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13



#	ARTICLE	IF	CITATIONS
1126	Natural killer cell exhaustion in SARS-CoV-2 infection. <i>Innate Immunity</i> , 2022, 28, 189-198.	1.1	5
1127	Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	15
1129	SARS-CoV-2 and cancer: the intriguing and informative cross-talk. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103488.	0.5	5
1130	COVID-19 and Fungal Diseases. <i>Antibiotics</i> , 2022, 11, 803.	1.5	5
1131	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1132	Major Histocompatibility Complex Class I Chain-Related $\hat{\pm}$ (MICA) STR Polymorphisms in COVID-19 Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6979.	1.8	1
1133	Monocytic-Myeloid Derived Suppressor Cells Suppress T-Cell Responses in Recovered SARS CoV2-Infected Individuals. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1134	Coronavirus disease 2019 (COVID-19) update: From metabolic reprogramming to immunometabolism. <i>Journal of Medical Virology</i> , 2022, 94, 4611-4627.	2.5	18
1135	Strategies to fight COVID-19: Beyond the difference between SARS-CoV-2 and Influenza virus. <i>International Journal of Sexual and Reproductive Health Care</i> , 2022, 5, 016-029.	0.1	0
1136	A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China. <i>International Journal of Medical Sciences</i> , 2022, 19, 1122-1130.	1.1	0
1137	DYNAMICS OF CERTAIN CLINICAL-BIOCHEMICAL PARAMETERS IN PATIENTS WITH INTERSTITIAL PNEUMONIA AFTER COVID-19 CORONAVIRUS DISEASE. <i>Bulletin of Problems Biology and Medicine</i> , 2022, 1, 225.	0.0	0
1138	The nervous system during COVID-19: Caught in the crossfire. <i>Immunological Reviews</i> , 2022, 311, 90-111.	2.8	9
1139	NKG2A Expression among CD8 Cells Is Associated with COVID-19 Progression in Hypertensive Patients: Insights from the BRACE CORONA Randomized Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3713.	1.0	7
1140	Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: a retrospective study. <i>BMJ Open</i> , 2022, 12, e061610.	0.8	5
1141	Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms. <i>PLoS Pathogens</i> , 2022, 18, e1010630.	2.1	14
1142	Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 369-392.	0.5	9
1143	Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	34
1144	Diagnosis and Prognosis of COVID-19 Disease Using Routine Blood Values and LogNNet Neural Network. <i>Sensors</i> , 2022, 22, 4820.	2.1	21

#	ARTICLE	IF	CITATIONS
1145	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
1146	Issues related to post-COVID-19 syndrome. <i>World Journal of Methodology</i> , 2022, 12, 224-234.	1.1	0
1147	NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients. <i>Cell Biochemistry and Function</i> , 2022, 40, 559-568.	1.4	5
1148	The sex and gender dimensions of COVID-19: A narrative review of the potential underlying factors. <i>Infection, Genetics and Evolution</i> , 2022, 103, 105338.	1.0	12
1149	COVID-19 and Tuberculosis: Two Knives in a Sheath. <i>Coronaviruses</i> , 2022, 03, .	0.2	1
1150	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. <i>Pharmaceutical Research</i> , 2022, 39, 2119-2134.	1.7	10
1151	Recruited and Tissue-Resident Natural Killer Cells in the Lung During Infection and Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1152	Pacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 and HIV-1-Derived RNA. <i>Journal of Innate Immunity</i> , 2023, 15, 96-106.	1.8	8
1153	In Vitro Exposure of Primary Human T Cells and Monocytes to Polyclonal Stimuli Reveals a Basal Susceptibility to Display an Impaired Cellular Immune Response and Develop Severe COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1154	Dengue and COVID-19: two sides of the same coin. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	16
1155	Pyroptotic Patterns in Blood Leukocytes Predict Disease Severity and Outcome in COVID-19 Patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1156	Mechanism of Huo-Xiang-Zheng-Qi in Preventing and Treating COVID-19: A Study Based on Network Pharmacology and Molecular Docking Techniques. <i>Natural Product Communications</i> , 2022, 17, 1934578X2211020.	0.2	0
1157	Innate immunity to SARS-CoV-2 infection: A review. <i>Epidemiology and Infection</i> , 0, , 1-49.	1.0	9
1158	The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update. <i>Journal of Medical Virology</i> , 2022, 94, 5128-5148.	2.5	12
1159	SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19. <i>Journal of Neurology</i> , 2022, 269, 4581-4603.	1.8	4
1160	Clinical progress in MSC-based therapies for the management of severe COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2022, 68, 25-36.	3.2	10
1161	Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113368.	2.5	6
1162	Long COVID and the cardiovascular system—elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. <i>Cardiovascular Research</i> , 2023, 119, 336-356.	1.8	53

#	ARTICLE	IF	CITATIONS
1163	Comparison between clinical characteristics and laboratory findings among patients with complicated and noncomplicated SARS-CoV-2 infection: A single-center experience from Shebin Al-Khaim, Egypt. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	1
1164	A Real Pandora's Box in Pandemic Times: A Narrative Review on the Acute Cardiac Injury Due to COVID-19. <i>Life</i> , 2022, 12, 1085.	1.1	11
1165	Can iron, zinc, copper and selenium status be a prognostic determinant in COVID-19 patients?. <i>Environmental Toxicology and Pharmacology</i> , 2022, 95, 103937.	2.0	12
1166	Identification of COVID-19-Specific Immune Markers Using a Machine Learning Method. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	11
1167	Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1168	Acute kidney injury associated to COVID-19 leads to a strong unbalance of circulant immune mediators. <i>Cytokine</i> , 2022, 157, 155974.	1.4	12
1169	Is IFN expression by NK cells a hallmark of severe COVID-19?. <i>Cytokine</i> , 2022, 157, 155971.	1.4	3
1170	Stem Cells: A Promising Therapeutic Target for COVID-19. <i>Stem Cell Discovery</i> , 2022, 12, 1-27.	0.5	1
1171	Investigation of respiratory tract coinfections in Coronavirus disease 2019 infected and suspected cases. <i>Åstanbul Kuzey Klinikleri</i> , 2022, , .	0.1	0
1172	Alterations of Blood Immune Cells in Elderly Patients with COVID-19 and with or without Pre-Existing Type 2 Diabetes. <i>Open Journal of Immunology</i> , 2022, 12, 41-63.	0.5	0
1173	Melatonin: Regulation of Viral Phase Separation and Epitranscriptomics in Post-Acute Sequelae of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8122.	1.8	7
1174	Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1816-1828.	1.4	9
1175	Herpes Simplex Virus 1 (HSV-1) Reactivation in Critically Ill COVID-19 Patients: A Brief Narrative Review. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1779-1791.	1.8	16
1176	Rural-urban outcome differences associated with COVID-19 hospitalizations in North Carolina. <i>PLoS ONE</i> , 2022, 17, e0271755.	1.1	16
1177	SARS-CoV-2-reactive IFN- $\gamma$ -producing CD4+ and CD8+ T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1178	Implications of NKG2A in immunity and immune-mediated diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
1179	Dysregulation of immunity in COVID-19 and SLE. <i>Inflammopharmacology</i> , 2022, 30, 1517-1531.	1.9	6
1180	Immune checkpoint inhibitors for the treatment of sepsis: insights from preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 885-894.	1.9	10

#	ARTICLE	IF	CITATIONS
1181	Cellular heterogeneity in disease severity and clinical outcome: Granular understanding of immune response is key. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1182	Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13.	0.7	5
1183	Immunological evaluation of patients with 2019 novel coronavirus pneumonia: CD4+ and CD16+ cells may predict severity and prognosis. <i>PLoS ONE</i> , 2022, 17, e0268712.	1.1	1
1184	A simple model of COVID-19 explains disease severity and the effect of treatments. <i>Scientific Reports</i> , 2022, 12, .	1.6	14
1185	Identification of Novel Therapeutic Candidates Against SARS-CoV-2 Infections: An Application of RNA Sequencing Toward mRNA Based Nanotherapeutics. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
1186	Importancia de los Interferones en la respuesta inmune antiviral contra SARS-CoV-2. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
1187	Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity. <i>Journal of Immunology Research</i> , 2022, 2022, 1-9.	0.9	9
1188	An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 207, 138-149.	2.5	21
1189	Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients. <i>Molecular Medicine</i> , 2022, 28, .	1.9	10
1190	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1191	Evaluation of Hematologic Parameters in Patients with COVID-19 Following Mesenchymal Stem Cell Therapy. <i>DNA and Cell Biology</i> , 2022, 41, 768-777.	0.9	0
1192	Dose Descriptors and Assessment of Risk of Exposure-Induced Death in Patients Undergoing COVID-19 Related Chest Computed Tomography. <i>Diagnostics</i> , 2022, 12, 2012.	1.3	4
1193	Correlation between thymic output and disease severity in critically ill COVID-19 patients: extended abstract. <i>Mediastinum</i> , 0, 6, 30-30.	0.6	0
1194	COVID-19 imparted immune manifestation can be combated by NLGP: Lessons from cancer research. <i>Cytokine</i> , 2022, 158, 155980.	1.4	0
1195	A Pilot Trial of Thymalfasin (Thymosin- $\alpha$ 1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. <i>Journal of Infectious Diseases</i> , 2023, 227, 226-235.	1.9	7
1196	Genetic predisposition to blood cell indices in relation to severe COVID-19. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	7
1197	Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function. <i>European Journal of Pharmacology</i> , 2022, 933, 175267.	1.7	6
1199	COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4

#	ARTICLE	IF	CITATIONS
1200	The Severity of COVID-19 Affects the Plasma Soluble Levels of the Immune Checkpoint HLA-G Molecule. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9736.	1.8	4
1201	Heterogenous CD8+ T Cell Maturation and "Polarization"™ in Acute and Convalescent COVID-19 Patients. <i>Viruses</i> , 2022, 14, 1906.	1.5	16
1202	Blood Transcriptomes of SARS-CoV-2-Infected Kidney Transplant Recipients Associated with Immune Insufficiency Proportionate to Severity. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 2108-2122.	3.0	6
1203	Proteomics research of SARS-CoV-2 and COVID-19 disease. <i>Medical Review</i> , 2022, 2, 427-445.	0.3	1
1204	Clinical characteristics and outcomes of patients with Herpes Zoster Infection in the context of SARS-CoV-2 infection. A case report and a systematic review. <i>Qatar Medical Journal</i> , 2022, 2022, .	0.2	3
1205	Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota. <i>World Journal of Clinical Infectious Diseases</i> , 0, 12, 50-60.	0.5	0
1206	Microbial and human transcriptional profiling of coronavirus disease 2019 patients: Potential predictors of disease severity. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
1207	COVID-19 vs. Cancer Immunosurveillance: A Game of Thrones within an Inflamed Microenvironment. <i>Cancers</i> , 2022, 14, 4330.	1.7	4
1208	Despite Vaccination: A Real-Life Experience of Severe and Life-Threatening COVID-19 in Vaccinated and Unvaccinated Patients. <i>Vaccines</i> , 2022, 10, 1540.	2.1	1
1209	COVID-19: imbalanced cell-mediated immune response drives to immunopathology. <i>Emerging Microbes and Infections</i> , 2022, 11, 2393-2404.	3.0	9
1210	PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical $\beta$ 2-coronavirus disease. <i>Science Advances</i> , 2022, 8, .	4.7	14
1211	Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. <i>Exploration of Immunology</i> , 2022, 2, 648-664.	1.7	1
1213	A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2022, 45, 389-395.	1.2	4
1214	COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211250.	0.4	6
1215	SARS-CoV-2-specific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer. <i>Immunology Letters</i> , 2022, 251-252, 38-46.	1.1	2
1216	Rethinking sepsis after a two-year battle with COVID-19. , 2022, 19, 1317-1318.		5
1217	Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development. <i>Current Microbiology</i> , 2022, 79, .	1.0	3
1218	Bioorthogonal Photoreactive Surfaces for Single-Cell Analysis of Intercellular Communications. <i>Journal of the American Chemical Society</i> , 2022, 144, 17980-17988.	6.6	4

#	ARTICLE	IF	CITATIONS
1219	Immunophenotyping characteristics of COVID-19 patients: Peripheral blood CD8+ HLA-DR+ T cells as a biomarker for mortality outcome. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
1221	Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1222	SARS-CoV-2 and HIV-1: So Different yet so Alike. <i>Immune Response at the Cellular and Molecular Level. International Journal of Medical Sciences</i> , 2022, 19, 1787-1795.	1.1	6
1223	Evaluation of prognostic markers in patients infected with SARS-CoV-2. <i>Open Life Sciences</i> , 2022, 17, 1360-1370.	0.6	0
1224	Immune checkpoint alterations and their blockade in COVID-19 patients. <i>Blood Science</i> , 2022, 4, 192-198.	0.4	2
1225	Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19. <i>Life</i> , 2022, 12, 1652.	1.1	1
1226	SARS-CoV-2 modulates inflammatory responses of alveolar epithelial type II cells via PI3K/AKT pathway. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1227	The importance of using routine laboratory tests in the diagnosis and prognosis of patients with coronavirus disease 2019: Shedding light on clinical laboratory data in COVID-19. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	2
1228	El elemento sexo en el COVID-19: Mecanismos diferenciales en la susceptibilidad, severidad y mortalidad de la enfermedad por SARS-CoV-2. <i>Revista Colombiana De Endocrinología, Diabetes &amp; Metabolismo</i> , 2022, 9, .	0.1	0
1229	Neuro-immune Interactions in Severe COVID-19 Infection. <i>Pathogens</i> , 2022, 11, 1256.	1.2	1
1230	Adaptive immunity to SARS-CoV-2 infection: A systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
1231	Development of Single-Cell Transcriptomics and Its Application in COVID-19. <i>Viruses</i> , 2022, 14, 2271.	1.5	1
1232	Prospects for the Use of Marine Sulfated Fucose-Rich Polysaccharides in Treatment and Prevention of COVID-19 and Post-COVID-19 Syndrome. <i>Russian Journal of Bioorganic Chemistry</i> , 2022, 48, 1109-1122.	0.3	2
1233	Immune system disturbances after a new coronavirus infection COVID-19. <i>Jurnal Infektologii</i> , 2022, 14, 26-37.	0.1	4
1234	COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. <i>Cellular Signalling</i> , 2023, 101, 110495.	1.7	11
1235	COVID-19 disease and immune dysregulation. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101401.	0.7	26
1236	Efficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortality. <i>Marmara Medical Journal</i> , 0, , .	0.2	0
1237	The IgG glycome of SARS-CoV-2 infected individuals reflects disease course and severity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9

#	ARTICLE	IF	CITATIONS
1238	Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients. <i>Cells</i> , 2022, 11, 3359.	1.8	4
1239	CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1240	SARS-CoV-2 ORF8: One protein, seemingly one structure, and many functions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
1241	A machine learning approach utilizing DNA methylation as an accurate classifier of COVID-19 disease severity. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
1242	The derived neutrophil to lymphocyte ratio can be the predictor of prognosis for COVID-19 Omicron BA.2 infected patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	17
1243	Combined plasma levels of IL-10 and testosterone, but not soluble HLA-G5, predict the risk of death in COVID-19 patients. <i>Andrology</i> , 2023, 11, 32-44.	1.9	5
1244	A comprehensive assessment of four whole blood stabilizers for flow cytometric analysis of leukocyte populations. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 313-324.	1.1	2
1245	ZnO nanoparticles and their properties as surface coating materials against coronavirus: viewpoint. , 2022, 14, 53-61.		4
1246	Epidemiology and Clinical Presentation of COVID-19 in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 1-26.	1.9	10
1247	Bioinformatics and systems biology approaches to identify molecular targeting mechanism influenced by COVID-19 on heart failure. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1249	Unbalanced networks and disturbed kinetics of serum soluble mediators associated with distinct disease outcomes in severe COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1250	Biomarkers of sequela in adult patients convalescing from COVID-19. <i>Advances in Biomarker Sciences and Technology</i> , 2022, , .	0.8	0
1251	SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	8
1252	Ageing, inflammaging and immunosenescence as risk factors of severe COVID-19. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	28
1253	Influence of SARS-COV-2 Infection on Cytokine Production by Mitogen-Stimulated Peripheral Blood Mononuclear Cells and Neutrophils in COVID-19 Intensive Care Unit Patients. <i>Microorganisms</i> , 2022, 10, 2194.	1.6	1
1254	Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities. <i>Clinical Immunology</i> , 2022, 245, 109177.	1.4	12
1255	Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. <i>International Immunopharmacology</i> , 2022, 113, 109428.	1.7	22
1257	Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19. <i>Clinical Immunology</i> , 2023, 246, 109209.	1.4	14

#	ARTICLE	IF	CITATIONS
1258	CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults. <i>Immunobiology</i> , 2023, 228, 152304.	0.8	2
1259	An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	11
1260	Targeting the Complementâ€“Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14340.	1.8	7
1261	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1262	Defective antifungal immunity in patients with COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1263	SARS-CoV-2 escapes direct NK cell killing through Nsp1-mediated downregulation of ligands for NKG2D. <i>Cell Reports</i> , 2022, 41, 111892.	2.9	13
1264	Clinical features and mortality predictors of older hospitalized patients with severe COVID-19 in Lima, PerÃº. <i>Journal of Gerontology and Geriatrics</i> , 0, , 1-10.	0.2	0
1265	Donor selection for adoptive cell therapy with CD45RAâˆ“ memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release. <i>Cytotherapy</i> , 2023, 25, 330-340.	0.3	2
1266	A possible viral interference between SARS-CoV-2 and varicella zoster virus. , 0, 2, 126.		0
1267	Effect of hyperglycemia on the immune function of COVID-19 patients with type 2 diabetes mellitus: a retrospective study. <i>PeerJ</i> , 0, 10, e14570.	0.9	2
1268	Concurrent infections of cells by two pathogens can enable a reactivation of the first pathogen and the second pathogen's accelerated T-cell exhaustion. <i>Heliyon</i> , 2022, 8, e11371.	1.4	2
1269	Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15122.	1.8	1
1270	Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofiling. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1271	Single-cell multiomics revealed the dynamics of antigen presentation, immune response and T cell activation in the COVID-19 positive and recovered individuals. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1272	The promising approach of MSCs therapy for COVID-19 treatment. <i>Cell and Tissue Banking</i> , 0, , .	0.5	0
1273	<scp>CD8</scp> <sup>+</sup> T cells mediate antiviral response in severe fever with thrombocytopenia syndrome. <i>FASEB Journal</i> , 2023, 37, .	0.2	1
1274	LAG-3 Contribution to T Cell Downmodulation during Acute Respiratory Viral Infections. <i>Viruses</i> , 2023, 15, 147.	1.5	2
1275	An Outlook on Dental Practices to Avoid the Oral Transmission of COVID-19. <i>Microorganisms</i> , 2023, 11, 146.	1.6	1



#	ARTICLE	IF	CITATIONS
1276	Proinflammatory and Thrombotic Manifestations and the Therapeutic Options of COVID-19. <i>Journal of Global Humanities and Social Sciences</i> , 2023, , 49-78.	0.3	0
1277	Prolonged SARS-CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy. <i>In Vivo</i> , 2023, 37, 461-467.	0.6	2
1278	An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight. <i>Molecules</i> , 2023, 28, 795.	1.7	8
1279	Adaptive immune system in severe COVID-19 patients in the first week of illness: A pilot study. <i>European Journal of Microbiology and Immunology</i> , 2023, , .	1.5	0
1280	Metabolism of NK cells during viral infections. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1281	Natural killer cells for antiviral therapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	3
1283	New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 181-195.	0.2	2
1284	T Cells Immunophenotyping and CD38 Overexpression as Hallmarks of the Severity of COVID-19 and Predictors of Patients' Outcomes. <i>Journal of Clinical Medicine</i> , 2023, 12, 710.	1.0	2
1285	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. <i>Vaccines</i> , 2023, 11, 101.	2.1	14
1286	Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation. <i>Trends in Microbiology</i> , 2023, 31, 644-656.	3.5	7
1287	A csecsemőmirigy T-sejtjeinek árszetelében átrejtvá vältözísok a COVID-19-pandémia alatt. <i>Orvosi Hetilap</i> , 2022, 163, 2062-2066.	0.1	0
1288	Kinetics of Immune Subsets in COVID-19 Patients Treated with Corticosteroids. <i>Viruses</i> , 2023, 15, 51.	1.5	5
1289	Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) for Immunomodulation in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS). <i>Journal of Clinical Medicine</i> , 2023, 12, 304.	1.0	3
1290	Immunomodulation in COVID-19. <i>IP Indian Journal of Immunology and Respiratory Medicine</i> , 2023, 7, 151-153.	0.1	0
1291	Coordinated Loss and Acquisition of NK Cell Surface Markers Accompanied by Generalized Cytokine Dysregulation in COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1996.	1.8	3
1292	Innate immune responses in COVID-19. , 2023, , 63-128.		0
1293	Immune responses in mildly versus critically ill COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	18
1294	Clinical Investigation of Leukocyte DNA Damage in COVID-19 Patients. <i>Current Issues in Molecular Biology</i> , 2023, 45, 963-974.	1.0	0

#	ARTICLE	IF	CITATIONS
1295	Sustained Cytotoxic Response of Peripheral Blood Mononuclear Cells from Unvaccinated Individuals Admitted to the ICU Due to Critical COVID-19 Is Essential to Avoid a Fatal Outcome. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1947.	1.2	0
1296	Hyperinflammatory disease and vasculitis-associated autoimmune disease pathogenesis by novel virulent pathogens inducing lymphocyte exhaustion and/or suppression. <i>Human Cell</i> , 2023, 36, 872-874.	1.2	1
1297	Severity of COVID-19 in Patients with Diarrhoea: A Systematic Review and Meta-Analysis. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 84.	0.9	1
1298	Therapeutic Potential of Nitric Oxide in the Management of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS). , 2023, , 249-258.		0
1299	Physical human Activity, Immunity and COVID-19. <i>Research Journal of Pharmacy and Technology</i> , 2023, , 278-286.	0.2	1
1300	The rs568408 variant in the IL-12A gene is associated with risk for COVID-19 in Iraqi patients. <i>Tzu Chi Medical Journal</i> , 2023, 35, 152.	0.4	0
1301	Possible role of IL-6 and IL-17 among COVID-19 patients. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1302	Natural killer cells in COVID-19: from infection, to vaccination and therapy. <i>Future Virology</i> , 2023, 18, 177-191.	0.9	11
1303	COPD, diabetes, lymphopenia, and increased LDH cause higher mortality in hospitalized COVID-19 patients. <i>MedComm</i> , 2023, 4, .	3.1	0
1304	&lt;i>In vitro&i> activity of human recombinant interferon gamma against SARS-CoV-2 virus. <i>Voprosy Virusologii</i> , 2023, 68, 26-36.	0.1	0
1305	Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome. <i>Pharmaceuticals</i> , 2023, 16, 537.	1.7	5
1306	Willingness of Healthcare Workers to Recommend or Receive a Third COVID-19 Vaccine Dose: A Cross-Sectional Study from Jordan. <i>Infectious Disease Reports</i> , 2023, 15, 210-221.	1.5	2
1307	Natural Products as a Potential Source of Promising Therapeutics for COVID-19 and Viral Diseases. <i>Evidence-based Complementary and Alternative Medicine</i> , 2023, 2023, 1-15.	0.5	4
1308	Systematic review with meta-analysis of active herpesvirus infections in patients with COVID-19: Old players on the new field. <i>International Journal of Infectious Diseases</i> , 2023, 130, 108-125.	1.5	13
1309	Lower NK cell numbers in children with untreated juvenile dermatomyositis during the COVID-19 pandemic. <i>Clinical Immunology Communications</i> , 2023, 3, 42-45.	0.5	4
1310	Effect of Cytomegalovirus Reactivation on Inflammatory Status and Mortality of Older COVID-19 Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6832.	1.8	3
1312	Natural killer cells in sepsis: Friends or foes?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1313	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20

#	ARTICLE	IF	CITATIONS
1314	Role of natural killer and B cell interaction in inducing pathogen specific immune responses. <i>International Reviews of Immunology</i> , 2023, 42, 304-322.	1.5	1
1315	COVID-19: A trigger of autoimmune diseases. <i>Cell Biology International</i> , 2023, 47, 848-858.	1.4	10
1316	The turning point of COVID-19 severity is associated with a unique circulating neutrophil gene signature. <i>Immunology</i> , 2023, 169, 323-343.	2.0	3
1317	Characteristics and Potential Roles of Natural Killer Cells During SARS-CoV-2 Infection. <i>Infectious Diseases &amp; Immunity</i> , 2023, 3, 29-35.	0.2	0
1318	Effect of thymalfasin (Thymosin- $\alpha$ 1) on reversing lymphocytopenia among patients with COVID-19. <i>International Immunopharmacology</i> , 2023, 116, 109831.	1.7	0
1319	Role of T cells in severe COVID-19 disease, protection, and long term immunity. <i>Immunogenetics</i> , 2023, 75, 295-307.	1.2	14
1320	A review on synthesis of antiviral drugs, in silico studies and their toxicity. <i>Journal of the Indian Chemical Society</i> , 2023, 100, 100936.	1.3	1
1321	Alterations in the immune system persist after one year of convalescence in severe COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1322	Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection. <i>Frontiers in Aging</i> , 0, 4, .	1.2	5
1323	Employing T-Cell Memory to Effectively Target SARS-CoV-2. <i>Pathogens</i> , 2023, 12, 301.	1.2	0
1324	The Role of Interferons in Long Covid Infection. <i>Journal of Interferon and Cytokine Research</i> , 2023, 43, 65-76.	0.5	2
1325	Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics. <i>BiolImpacts</i> , 0, , .	0.7	0
1326	Role of the immune system in COVID-19 pathomorphogenesis. <i>Genes and Cells</i> , 2020, 15, 75-87.	0.2	0
1327	Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity. <i>Vaccines</i> , 2023, 11, 524.	2.1	3
1328	Increased NKG2A+CD8+ T-cell exhaustion in patients with adenomyosis. <i>Mucosal Immunology</i> , 2023, 16, 121-134.	2.7	1
1329	Current status in cellular-based therapies for prevention and treatment of COVID-19. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 0, , 1-25.	2.7	0
1330	COVID-19 as a polymorphic inflammatory spectrum of diseases: a review with focus on the brain. <i>Acta Neuropsychiatrica</i> , 0, , 1-22.	1.0	1
1331	COVID-19 Adverse Outcomes in Immunocompromised Patients. <i>International Journal of Cancer Management</i> , 2023, 16, .	0.2	0

#	ARTICLE	IF	CITATIONS
1332	The role of immune activation and antigen persistence in acute and long COVID. <i>Journal of Investigative Medicine</i> , 2023, 71, 545-562.	0.7	17
1333	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1334	COVID-19 and Frailty. <i>Vaccines</i> , 2023, 11, 606.	2.1	4
1335	Severe COVID-19 versus multisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection. <i>European Respiratory Review</i> , 2023, 32, 220197.	3.0	2
1336	NK cells in COVID-19—from disease to vaccination. <i>Journal of Leukocyte Biology</i> , 2023, 114, 507-512.	1.5	2
1337	Cellular Immune Profiling of Lung and Blood Compartments in Patients with SARS-CoV-2 Infection. <i>Pathogens</i> , 2023, 12, 442.	1.2	2
1338	Hemophagocytic Syndrome and COVID-19: A Comprehensive Review. <i>Cureus</i> , 2023, , .	0.2	0
1339	Association between the overall burden of comorbidity and Ct values among the older patients with Omicron infection: Mediated by inflammation. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1341	Immune Dynamics Involved in Acute and Convalescent COVID-19 Patients. <i>Immuno</i> , 2023, 3, 86-111.	0.6	1
1342	Pathogen regulatory RNA usage enables chronic infections, T-cell exhaustion and accelerated T-cell exhaustion. <i>Molecular and Cellular Biochemistry</i> , 0, , .	1.4	0
1343	Longitudinal analysis of electrolyte prolife in intensive care COVID-19 patients. <i>Egyptian Journal of Anaesthesia</i> , 2023, 39, 266-276.	0.2	0
1344	Cell-Based Biomaterials for Coronavirus Disease 2019 Prevention and Therapy. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	0
1345	Hepatobiliary system and intestinal injury in new coronavirus infection (COVID-19): A retrospective study. <i>World Journal of Clinical Cases</i> , 0, 11, 2226-2236.	0.3	0
1346	Non-classical HLA class I molecules and their potential role in viral infections. <i>Human Immunology</i> , 2023, 84, 384-392.	1.2	3
1347	Intertwined Dysregulation of Ribosomal Proteins and Immune Response Delineates SARS-CoV-2 Vaccination Breakthroughs. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	2
1348	Emerging roles of SARS-CoV-2 Spike-ACE2 in immune evasion and pathogenesis. <i>Trends in Immunology</i> , 2023, 44, 424-434.	2.9	5
1349	Relationship between Vitamin D and Immunity in Older People with COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 5432.	1.2	1
1350	Gut distress and intervention via communications of SARS-CoV-2 with mucosal exposome. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	0

#	ARTICLE	IF	CITATIONS
1351	Repurposed Drugs/Potential Pharmacological Agents Targeting Cytokine Release and Induction of Coagulation in COVID-19. , 2023, , 100-136.		0
1385	The interferon-stimulated genes are plausibly a primary genetic locus for genetically enabling hyperinflammatory and autoimmune diseases and lymphocyte exhaustion. Human Cell, 0, , .	1.2	0
1387	The kinetics of inhibitory immune checkpoints during and post-COVID-19: the knowns and unknowns. Clinical and Experimental Medicine, 0, , .	1.9	0
1424	Cytokine storm and translating IL-6 biology into effective treatments for COVID-19. Frontiers of Medicine, 2023, 17, 1080-1095.	1.5	0
1430	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0
1439	Effect of Curcumin on the Process of Neuroinflammation Caused by COVID-19. , 2023, , 293-310.		0